Non-ischemic CardiomyopathyAINICMNCT06607471

Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.

An observational study of Non-ischemic Cardiomyopathy and Dilated Cardiomyopathy (DCM), run by Scientific Institute San Raffaele at 1 site in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and older
Conditions the study is for: Non-ischemic Cardiomyopathy, Dilated Cardiomyopathy (DCM), Hypertrophic Cardiomyopathy (HCM)
What is being tested?: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation and Support treatment, cardiac medical treatment, aetiology-specific treatment
How many people: 15,000 participants
Where: 1 siteItaly
Study dates: 30 Jan 2018to 31 Dec 2035
How long will I take part?: 30 Years
Phase: Observational
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Study population: This is an international registry. Enrolment of NICM patients will be performed without restrictions concerning age, gender, ethnicity, social, political, or economical status. Both inpatients and outpatients will be suitable for enrollment. Beyond clinically suspected or proven NICMs, genotype-positive familial cases will be enrolled. The expected sample size is 150000, of whom 5000 will be enrolled at San Raffaele Hospital.

Who may be able to join

Written informed consent. For pediatric patients, consent will be obtained by parents, according to the laws applicable in each of the participating countries.
Clinical suspicion of NICM, and/or proven diagnosis of any NICM and/or genotype consistent with any NICM.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

Who cannot join

Absent informed consent.
Proven diagnosis of cardiac disease alternative to NICM.
Lack of diagnostic workup suitable for diagnosing NICM, detecting arrhythmias, or detecting M-Infl.
For patients retrospectively enrolled: lack of active status of follow-up at the enrolling center.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Giovanni Peretto, MD contact

+39 0226437482

peretto.giovanni@hsr.it

Simone Sala, MD contact

+39 0226437483

sala.simone@hsr.it

Italy1 site, 1 recruiting

IRCCS San Raffaele Scientific Institute
Milan, Milano, 20132
Giovanni Peretto, MD, +39 0226437482, peretto.giovanni@hsr.it
Simone Sala, MD, +39 0226437483, sala.simone@hsr.it
Recruiting

Other trials in Italy

About this study

Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the myocardium. The main identified forms include dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic cardiomyopathy proper (ACM). More recently, further forms of cardiomyopathy have been described, less common and not uniquely classifiable, including: uncompressed myocardium (LVNC), peripartum cardiomyopathy (PPCM), structural correlates of arrhythmogenic mitral valve prolapse (AMVP), Anderson-Fabry disease (AFD), NICM associated with multi- system neuromuscular or autoimmune diseases, lysosomal diseases, glycogenosis, mitochondrial cytopathies and canal diseases with structural substrates. Finally, there are "overlap" forms, characterized by the sharing in the same subject of characteristic aspects of two or more of the above- mentioned diseases; and of the "undefined" forms, which to date do not reach the diagnostic criteria for any of the above-mentioned diseases.

To the best of current knowledge, there are two points discovered in scientific research, namely the description of the arrhythmogenic and "inflammatory" phenotypes in a broad sense, which are summarized here with the acronym AINICM. In detail:

Arrhythmic manifestations account for the arrhythmogenic component of AINICM, which is not limited to ACM proper. In fact, most of the above diseases have a non-arrhythmic clinical presentation and a prevailing tendency to evolve towards a picture of cardiovascular decompensation. Although sudden arrhythmic death has been described throughout the spectrum of AINICM, early arrhythmic manifestations of such diseases have an unknown prevalence, an uncertain association with different disease genotypes and phenotypes, and still uncertain predictivity of long-term arrhythmic risk. At the same time, optimal diagnostic and therapeutic pathways in arrhythmias associated with AINICM are still being studied.
Myocardial inflammation (M-Infl) accounts for the inflammatory component of AINICM, and has recently been described in association with many AINICM on a genetic basis, including undefined and arrhythmic forms. The data is of high interest not only in the diagnostic, but also in prognostic and therapeutic field. In fact, on the one hand the presence of M-Infl seems to have a physio- pathological role in AINICM; on the other, as already known in myocarditis, the optimal therapeutic paths of arrhythmias may differ in patients with and without M-Infl; in particular, also in the light of the preliminary data available in adult and paediatric AINICM, the inflammatory forms are expected to respond better to immunosuppressive therapy, the arrhythmogenic ones to an ablative therapy with frequent need of implantation of cardiac devices.

Based on the clinical presentation, NICM patients will be divided into arrhythmic (AINICM) and non-arrhythmic patients as study and control groups , respectively. The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). Clinical presentations other than arrhythmic, including chest pain and heart failure, will define the control group. In parallel, as shown in Figure 1, patients with any evidence of M-Infl will be compared with those showing no signs of M-Infl.

Read the detailed description

This study aims to collect clinical data of both retrospective and prospective patients with suspected or proven NICMs in a registry. The scope of the registry is to answer multiple unsolved questions in the field of AINICM as described below:

Improving the diagnostic workup. While genetic test and cardiac magnetic resonance (CMR) constitute the gold standard dagnostic techniques for NICM, it is known that; A) the yield of genetic test is low in NICM; B) the diagnostic performance of CMR may be limited in AINICM, because of cardiac device-related artifacts and/or irregular heartbeat. In this setting, alternative diagnostic techniques, namely computed tomography (CT) scan, positron emission tomography (PET), electroanatomical map (EAM) and endomyocardial biopsy (EMB) may be clinically helpful, as recommended for the investigation of many arrhythmogenic substrates.
Identifying disease-specific signatures. Genotype-phenoype associations are expected to benefit from a multimodal and multiparametric approach, in order to allow etiology-specific features in AINICM. Most of the current signatures are limited to combined genotype-CMR studies. Signatures would likely benefit from implementing additional parameters, including arrhythmia features and myocadial inflammatory status.
Working our models for risk prediction. Outcomes and arrhythmic risk stratification remain uncertain for most NICM. Based on an advanced multimodal workup, multiparametric risk scores may be created and subsequenlty validated, in order to predict the arrhythmic risk of specific cardiomyopathies. This would improve and refine the scores currently available for a limited number of NICM, such as HCM, classic right ventricular ACM, or cardiomyopathies secondary to LMNA gene mutation. Parameters from clinical arrhythmology and cardiac electrophysiology, as well as those related to inflammation, may improve the current status of the art about risk prediction.
Tailoring treatment strategies. A multimodal (i.e. by use of multiple diagnostic techniques) and multidisciplinary (i.e. by means of a team of cardiac electrophysiologists, cardiologists, radiologists, geneticists, immunologists, cardiac pathologists, pediatricians) model may help improving therapeutic strategies in AINICM, as already demonstrated in myocarditis. In detail, treatment options will include guideline-directed cardiological treatment, implantable cardiac devices, antiarrhythmic drugs, immunomodulating agents and catheter ablation of arrhythmias. In this setting, the coordinating center is an internationally recognized third-level referral center for the management of ventricular arrhythmias, and already has advanced facilities, including a dedicated multidisciplinary disease unit for myocarditis and inflammatory cardiomyopathies. In this setting, preliminary evidence suggests a potential benefit from targeting M-Infl even in NICM and AINICM.
Allowing direct comparison among specific NICM subgroups. Extensive inclusion criteria, allowing the entry of all NICM in a common registry with homogeneous variables would enable the direct comparison of different AINICM types, by means of multiparametric and multimodal characterization, for the first time including both the electrophysiological and inflammatory viewpoints. This is expected to significantly advance the status of knowledge in the field of NICM.

Conditions: Non-ischemic Cardiomyopathy, Dilated Cardiomyopathy (DCM), Hypertrophic Cardiomyopathy (HCM), Restrictive Cardiomyopathy, Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Left Ventricular Noncompaction
Being tested: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation, Support treatment, cardiac medical treatment, aetiology-specific treatment
Keywords: Arrhythmogenic cardiomyopathy, Adverse event, Anderson-Fabry disease, Arrhythmic and Inflammatory Non-ischemic cardiomyopathy, Arrhythmogenic mitral valve prolapse, Anti tachycardia pacing, Bradiarrhythmias, Cardiac magnetic resonance, Cardiac resynchronization therapy with defibrillator, Computed tomography, Development Safety Update Report, Ethics Committee, Electroanatomical map, Electrocardiogram, Endomyocardial biopsy, Good Clinical Practice, Hypertrophic cardiomyopathy, Implantable cardioverter defibrillator, Informed Consent Form, International Conference on Harmonization
Medical subject headings: Cardiomyopathy, Dilated, Cardiomyopathy, Hypertrophic, Cardiomyopathy, Restrictive, Arrhythmogenic Right Ventricular Dysplasia, Peripartum Cardiomyopathy, Fabry Disease, Ventricular Fibrillation, Myocarditis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablationOther
Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
Support treatment, cardiac medical treatment, aetiology-specific treatmentOther
Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.

Study groups in NCT06607471
Study group	Role	What they receive
Arrhythmic and Inflammatory (AINICM)		The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). The arrhythmogenic and the inflammatory non-ischemic cardiomyopathies (AINICM) will be characterized by means of a multimodal diagnostic workup, which is a combination ofgenetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry. Receives: Other: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Non-arrhythmic and inflammatory (INICM)		The inflammatory component will be diagnosed by means of a multidisciplinary workup (i.e. EMB, PET). Receives: Other: Support treatment, cardiac medical treatment, aetiology-specific treatment
Arrhythmic and Non-inflammatory (ANICM)		The arrhythmic component will be diagnosed by means of a multidisciplinary work-up (i.e. SAECG, Arrhythmia monitoring, Stress test, CT scan, EAM, Electrophysiological test) Receives: Other: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Non-arrhythmic and Non-inflammatory (NICM)		NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge. Receives: Other: Support treatment, cardiac medical treatment, aetiology-specific treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Measured: At year 30
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At baseline
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 5
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 10
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 15
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 20
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 25
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Measured: At year 30
Identification of DCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of DCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of DCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of DCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of DCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of DCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of DCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of HCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of HCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of HCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of HCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of HCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of HCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of HCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of RCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of RCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of RCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of RCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of RCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of RCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of RCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of ACM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of ACM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of ACM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of ACM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of ACM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of ACM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of ACM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of LVNC-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of LVNC-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of LVNC-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of LVNC-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of LVNC-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of LVNC-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of LVNC-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of AMVP-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of AMVP-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of AMVP-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of AMVP-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of AMVP-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of AMVP-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of AMVP-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of PPCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of PPCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of PPCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of PPCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of PPCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of PPCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of PPCM-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of AFD-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of AFD-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of AFD-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of AFD-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of AFD-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of AFD-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of AFD-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of storage and dysmetabolic diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of storage and dysmetabolic diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of storage and dysmetabolic diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of storage and dysmetabolic diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of storage and dysmetabolic diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of storage and dysmetabolic diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of storage and dysmetabolic diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of mitochondrial diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of mitochondrial diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of mitochondrial diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of mitochondrial diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of mitochondrial diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of mitochondrial diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of mitochondrial diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of channelopathies with structural changes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of channelopathies with structural changes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of channelopathies with structural changes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of channelopathies with structural changes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of channelopathies with structural changes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of channelopathies with structural changes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of channelopathies with structural changes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of overlapping phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of overlapping phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of overlapping phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of overlapping phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of overlapping phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of overlapping phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of overlapping phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Identification of undefined phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At baseline
Identification of undefined phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 5
Identification of undefined phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 10
Identification of undefined phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 15
Identification of undefined phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 20
Identification of undefined phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 25
Identification of undefined phenotypes-specific signatures
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Measured: At year 30
Differences in incidence of major events during follow-up in different NICMs
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Differences in incidence of major events during follow-up in different NICMs
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At year 5
Differences in incidence of major events during follow-up in different NICMs
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At year 10
Differences in incidence of major events during follow-up in different NICMs
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At year 15
Differences in incidence of major events during follow-up in different NICMs
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At year 20
Differences in incidence of major events during follow-up in different NICMs
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At year 25
Differences in incidence of major events during follow-up in different NICMs
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At year 30
Occurrence of major cardiac events in DCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in DCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in DCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 3 years
Occurrence of major cardiac events in DCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in DCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 15 years
Occurrence of major cardiac events in DCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 20 years
Occurrence of major cardiac events in DCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 25 years
Occurrence of major cardiac events in DCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in HCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in HCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 3 years
Occurrence of major cardiac events in HCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in HCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in HCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 15 years
Occurrence of major cardiac events in HCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 20 years
Occurrence of major cardiac events in HCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 25 years
Occurrence of major cardiac events in HCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in RCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in RCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 3 years
Occurrence of major cardiac events in RCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in RCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in RCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 15 years
Occurrence of major cardiac events in RCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 20 years
Occurrence of major cardiac events in RCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 25 years
Occurrence of major cardiac events in RCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in ACM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in ACM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 3 years
Occurrence of major cardiac events in ACM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in ACM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in ACM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 15 years
Occurrence of major cardiac events in ACM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 20 years
Occurrence of major cardiac events in ACM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 25 years
Occurrence of major cardiac events in ACM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in LVNC
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in LVNC
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in LVNC
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in LVNC
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in AMVP
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in AMVP
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in AMVP
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in AMVP
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in PPCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in PPCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in PPCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in PPCM
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in AFD
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in AFD
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in AFD
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in AFD
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in storage and dysmetabolic diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in storage and dysmetabolic diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in storage and dysmetabolic diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in storage and dysmetabolic diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in mitochondrial diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in mitochondrial diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in mitochondrial diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in mitochondrial diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in channelopathies with structural changeschannelopathies with structural changes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in channelopathies with structural changes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in channelopathies with structural changes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in channelopathies with structural changes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in overlapping phenotypes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in overlapping phenotypes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in overlapping phenotypes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in overlapping phenotypes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Occurrence of major cardiac events in undefined phenotypes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 1 year
Occurrence of major cardiac events in undefined phenotypes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 5 years
Occurrence of major cardiac events in undefined phenotypes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 10 years
Occurrence of major cardiac events in undefined phenotypes
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.
Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Measured: At 30 years

Secondary outcomes (1765)

Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
presence; type; quantification; pattern
Measured: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
presence; type; quantification; pattern
Measured: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
presence; type; quantification; pattern
Measured: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
presence; type; quantification; pattern
Measured: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
presence; type; quantification; pattern
Measured: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
presence; type; quantification; pattern
Measured: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
presence; type; quantification; pattern
Measured: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
presence; type; quantification; pattern
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At baseline
Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 5 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 10 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 15 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 20 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 25 years
Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
correlation between M-Infl and arrhythmia type and ECG features
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
correlation between EMB sampling site and localization of substrate correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
correlation between EMB sampling site and localization of substrate
Measured: At baseline
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
correlation between EMB sampling site and localization of substrate
Measured: At 5 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
correlation between EMB sampling site and localization of substrate
Measured: At 10 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
correlation between EMB sampling site and localization of substrate
Measured: At 15 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
correlation between EMB sampling site and localization of substrate
Measured: At 20 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
correlation between EMB sampling site and localization of substrate
Measured: At 25 years
Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
correlation between EMB sampling site and localization of substrate
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in DCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in DCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in DCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in DCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in DCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in DCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in DCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in HCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in HCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in HCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in HCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in HCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in HCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in HCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in RCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in RCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in RCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in RCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in RCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in RCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in RCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in ACM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in ACM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in ACM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in ACM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in ACM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in ACM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in ACM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in LVNC
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in LVNC
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in LVNC
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in LVNC
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in LVNC
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in LVNC
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in LVNC
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in AMVP
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in AMVP
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in AMVP
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in AMVP
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in AMVP
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in AMVP
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in AMVP
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in PPCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in PPCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in PPCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in PPCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in PPCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in PPCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in PPCM
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in AFD
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in AFD
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in AFD
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in AFD
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in AFD
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in AFD
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in AFD
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 30 years
Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At baseline
Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 5 years
Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 10 years
Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 15 years
Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 20 years
Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 25 years
Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
Investestigating the role of EMB guided by electroanatomical map in diagnosis
Measured: At 30 years
Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Evaluation of healing timing of M-Infl in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Evaluation of healing timing of M-Infl in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Evaluation of healing timing of M-Infl in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Evaluation of healing timing of M-Infl in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Evaluation of healing timing of M-Infl in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Evaluation of healing timing of M-Infl in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Evaluation of healing timing of M-Infl in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.
This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.
This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.
This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.
This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.
This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.
This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.
This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Evaluation of coronary microvascular disease in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Evaluation of coronary microvascular disease in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Evaluation of coronary microvascular disease in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Evaluation of coronary microvascular disease in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Evaluation of coronary microvascular disease in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Evaluation of coronary microvascular disease in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Evaluation of coronary microvascular disease in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Assessment of myocardial ischemia in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Assessment of myocardial ischemia in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Assessment of myocardial ischemia in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Assessment of myocardial ischemia in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Assessment of myocardial ischemia in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Assessment of myocardial ischemia in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Assessment of myocardial ischemia in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Assessment of autoimmunity in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Assessment of autoimmunity in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Assessment of autoimmunity in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Assessment of autoimmunity in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Assessment of autoimmunity in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Assessment of autoimmunity in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Assessment of autoimmunity in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Assessment of hemodynamic changes in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Assessment of hemodynamic changes in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Assessment of hemodynamic changes in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Assessment of hemodynamic changes in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Assessment of hemodynamic changes in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Assessment of hemodynamic changes in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Assessment of hemodynamic changes in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Multimodal multiparametric imaging investigation of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Multimodal multiparametric imaging investigation of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Multimodal multiparametric imaging investigation of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Multimodal multiparametric imaging investigation of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Multimodal multiparametric imaging investigation of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Multimodal multiparametric imaging investigation of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Multimodal multiparametric imaging investigation of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Evaluation of differential diagnosis between NICMs and other cardiac diseases
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Evaluation of differential diagnosis between NICMs and other cardiac diseases
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Evaluation of differential diagnosis between NICMs and other cardiac diseases
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Evaluation of differential diagnosis between NICMs and other cardiac diseases
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Evaluation of differential diagnosis between NICMs and other cardiac diseases
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Evaluation of differential diagnosis between NICMs and other cardiac diseases
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Evaluation of differential diagnosis between NICMs and other cardiac diseases
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Analysis of correlation between local and systemic/peripheral inflammation in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Analysis of correlation between local and systemic/peripheral inflammation in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Analysis of correlation between local and systemic/peripheral inflammation in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Analysis of correlation between local and systemic/peripheral inflammation in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Analysis of correlation between local and systemic/peripheral inflammation in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Analysis of correlation between local and systemic/peripheral inflammation in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Analysis of correlation between local and systemic/peripheral inflammation in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Diagnostic value of extracardiac diagnostic techniques in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At baseline
Diagnostic value of extracardiac diagnostic techniques in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Diagnostic value of extracardiac diagnostic techniques in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Diagnostic value of extracardiac diagnostic techniques in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Diagnostic value of extracardiac diagnostic techniques in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Diagnostic value of extracardiac diagnostic techniques in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Diagnostic value of extracardiac diagnostic techniques in NICMs
NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Occurrence of minor events in DCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 1 year
Occurrence of minor events in DCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 3 years
Occurrence of minor events in DCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Occurrence of minor events in DCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Occurrence of minor events in DCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Occurrence of minor events in DCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Occurrence of minor events in DCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Occurrence of minor events in DCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Occurrence of minor events in HCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 1 year
Occurrence of minor events in HCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 3 years
Occurrence of minor events in HCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Occurrence of minor events in HCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Occurrence of minor events in HCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Occurrence of minor events in HCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Occurrence of minor events in HCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Occurrence of minor events in HCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Occurrence of minor events in RCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 1 year
Occurrence of minor events in RCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 3 years
Occurrence of minor events in RCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Occurrence of minor events in RCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Occurrence of minor events in RCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Occurrence of minor events in RCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Occurrence in minor events in RCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Occurrence of minor events in RCM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Occurrence of minor events in ACM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 1 year
Occurrence of minor events in ACM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 3 years
Occurrence of minor events in ACM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Occurrence of minor events in ACM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Occurrence of minor events in ACM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Occurrence of minor events in ACM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Occurrence of minor events in ACM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Occurrence of minor events in ACM
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Occurrence of minor events in distinct cardiomyopathic phenotypes that have been described in some diseases
left ventricular noncompaction (LVNC), arrhythmogenic mitral valve prolapse (AMVP), peripartum cardiomyopathy (PPCM), Anderson-Fabry disease (AFD), storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases.
Minor events include non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 1 year
Occurrence of minor events in distinct cardiomyopathic phenotypes have been described in some diseases
left ventricular noncompaction (LVNC), arrhythmogenic mitral valve prolapse (AMVP), peripartum cardiomyopathy (PPCM), Anderson-Fabry disease (AFD), storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases.
Minor events include non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Occurrence of minor events in distinct cardiomyopathic phenotypes that have been described in some diseases
left ventricular noncompaction (LVNC), arrhythmogenic mitral valve prolapse (AMVP), peripartum cardiomyopathy (PPCM), Anderson-Fabry disease (AFD), storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases.
Minor events include non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Occurrence of minor events in distinct cardiomyopathic phenotypes that have been described in some diseases
left ventricular noncompaction (LVNC), arrhythmogenic mitral valve prolapse (AMVP), peripartum cardiomyopathy (PPCM), Anderson-Fabry disease (AFD), storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases.
Minor events include non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Occurrence of minor events in overlapping and undefined phenotypes
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 1 year
Occurrence of minor events in overlapping and undefined phenotypes
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Occurrence of minor events in overlapping and undefined phenotypes
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Occurrence of minor events in overlapping and undefined phenotypes
non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Identification of biomarkers associated with treatment response for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Identification of biomarkers associated with treatment response for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Identification of biomarkers associated with treatment response for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Identification of biomarkers associated with treatment response for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Identification of biomarkers associated with treatment response for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Identification of biomarkers associated with treatment response for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Identification of biomarkers associated with treatment response for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Identification of biomarkers associated with treatment response for NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Identification of cost-effective multimodal and multiparametric risk scores for NICMs
These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Identification of cost-effective multimodal and multiparametric risk scores for NICMs
These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Identification of cost-effective multimodal and multiparametric risk scores for NICMs
These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Identification of cost-effective multimodal and multiparametric risk scores for NICMs
These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Identification of cost-effective multimodal and multiparametric risk scores for NICMs
These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Identification of cost-effective multimodal and multiparametric risk scores for NICMs
These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Identification of cost-effective multimodal and multiparametric risk scores for NICMs
These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Identification of cost-effective multimodal and multiparametric risk scores for NICMs
These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Assessment of the prognostic value of arrhythmias in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Assessment of the prognostic value of arrhythmias in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Assessment of the prognostic value of arrhythmias in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Assessment of the prognostic value of arrhythmias in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Assessment of the prognostic value of arrhythmias in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Assessment of the prognostic value of arrhythmias in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Assessment of the prognostic value of arrhythmias in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Assessment of the prognostic value of arrhythmias in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 1 year
Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 3 years
Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 5 years
Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 10 years
Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 15 years
Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 20 years
Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 25 years
Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: At 30 years
Assessment of epidemiology signatures in DCM
Measured: At baseline
Assessment of epidemiology signatures in DCM
Measured: At 5 years
Assessment of epidemiology signatures in DCM
Measured: At 10 years
Assessment of epidemiology signatures in DCM
Measured: At 15 years
Assessment of epidemiology signatures in DCM
Measured: At 20 years
Assessment of epidemiology signatures in DCM
Measured: At 25 years
Assessment of epidemiology signatures in DCM
Measured: At 30 years
Assessment of epidemiology signatures in HCM
Measured: At baseline
Assessment of epidemiology signatures in HCM
Measured: At 5 years
Assessment of epidemiology signatures in HCM
Measured: At 10 years
Assessment of epidemiology signatures in HCM
Measured: At 15 years
Assessment of epidemiology signatures in HCM
Measured: At 20 years
Assessment of epidemiology signatures in HCM
Measured: At 25 years
Assessment of epidemiology signatures in HCM
Measured: At 30 years
Assessment of epidemiology signatures in RCM
Measured: At baseline
Assessment of epidemiology signatures in RCM
Measured: At 5 years
Assessment of epidemiology signatures in RCM
Measured: At 10 years
Assessment of epidemiology signatures in RCM
Measured: At 15 years
Assessment of epidemiology signatures in RCM
Measured: At 20 years
Assessment of epidemiology signatures in RCM
Measured: At 25 years
Assessment of epidemiology signatures in RCM
Measured: At 30 years
Assessment of epidemiology signatures in ACM
Measured: At baseline
Assessment of epidemiology signatures in ACM
Measured: At 5 years
Assessment of epidemiology signatures in ACM
Measured: At 10 years
Assessment of epidemiology signatures in ACM
Measured: At 15 years
Assessment of epidemiology signatures in ACM
Measured: At 20 years
Assessment of epidemiology signatures in ACM
Measured: At 25 years
Assessment of epidemiology signatures in ACM
Measured: At 30 years
Assessment of epidemiology signatures in LVNC
Measured: At baseline
Assessment of epidemiology signatures in LVNC
Measured: At 5 years
Assessment of epidemiology signatures in LVNC
Measured: At 10 years
Assessment of epidemiology signatures in LVNC
Measured: At 15 years
Assessment of epidemiology signatures in LVNC
Measured: At 20 years
Assessment of epidemiology signatures in LVNC
Measured: At 25 years
Assessment of epidemiology signatures in LVNC
Measured: At 30 years
Assessment of epidemiology signatures in AMVP
Measured: At baseline
Assessment of epidemiology signatures in AMVP
Measured: At 5 years
Assessment of epidemiology signatures in AMVP
Measured: At 10 years
Assessment of epidemiology signatures in AMVP
Measured: At 15 years
Assessment of epidemiology signatures in AMVP
Measured: At 20 years
Assessment of epidemiology signatures in AMVP
Measured: At 25 years
Assessment of epidemiology signatures in AMVP
Measured: At 30 years
Assessment of epidemiology signatures in PPCM
Measured: At baseline
Assessment of epidemiology signatures in PPCM
Measured: At 5 years
Assessment of epidemiology signatures in PPCM
Measured: At 10 years
Assessment of epidemiology signatures in PPCM
Measured: At 15 years
Assessment of epidemiology signatures in PPCM
Measured: At 20 years
Assessment of epidemiology signatures in PPCM
Measured: At 25 years
Assessment of epidemiology signatures in PPCM
Measured: At 30 years
Assessment of epidemiology signatures in AFD
Measured: At baseline
Assessment of epidemiology signatures in AFD
Measured: At 5 years
Assessment of epidemiology signatures in AFD
Measured: At 10 years
Assessment of epidemiology signatures in AFD
Measured: At 15 years
Assessment of epidemiology signatures in AFD
Measured: At 20 years
Assessment of epidemiology signatures in AFD
Measured: At 25 years
Assessment of epidemiology signatures in AFD
Measured: At 30 years
Assessment of epidemiology signatures in storage and dysmetabolic diseases
Measured: At baseline
Assessment of epidemiology signatures in storage and dysmetabolic diseases
Measured: At 5 years
Assessment of epidemiology signatures in storage and dysmetabolic diseases
Measured: At 10 years
Assessment of epidemiology signatures in storage and dysmetabolic diseases
Measured: At 15 years
Assessment of epidemiology signatures in storage and dysmetabolic diseases
Measured: At 20 years
Assessment of epidemiology signatures in storage and dysmetabolic diseases
Measured: At 25 years
Assessment of epidemiology signatures in storage and dysmetabolic diseases
Measured: At 30 years
Assessment of epidemiology signatures in mitochondrial diseases
Measured: At baseline
Assessment of epidemiology signatures in mitochondrial diseases
Measured: At 5 years
Assessment of epidemiology signatures in mitochondrial diseases
Measured: At 10 years
Assessment of epidemiology signatures in mitochondrial diseases
Measured: At 15 years
Assessment of epidemiology signatures in mitochondrial diseases
Measured: At 20 years
Assessment of epidemiology signatures in mitochondrial diseases
Measured: At 25 years
Assessment of epidemiology signatures in mitochondrial diseases
Measured: At 30 years
Assessment of epidemiology signatures in channelopathies with structural changes
Measured: At baseline
Assessment of epidemiology signatures in channelopathies with structural changes
Measured: At 5 years
Assessment of epidemiology signatures in channelopathies with structural changes
Measured: At 10 years
Assessment of epidemiology signatures in channelopathies with structural changes
Measured: At 15 years
Assessment of epidemiology signatures in channelopathies with structural changes
Measured: At 20 years
Assessment of epidemiology signatures in channelopathies with structural changes
Measured: At 25 years
Assessment of epidemiology signatures in channelopathies with structural changes
Measured: At 30 years
Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At baseline
Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 5 years
Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of epidemiology signatures in overlapping and undefined phenotypes
Measured: At baseline
Assessment of epidemiology signatures in overlapping and undefined phenotypes
Measured: At 5 years
Assessment of epidemiology signatures in overlapping and undefined phenotypes
Measured: At 10 years
Assessment of epidemiology signatures in overlapping and undefined phenotypes
Measured: At 15 years
Assessment of epidemiology signatures in overlapping and undefined phenotypes
Measured: At 20 years
Assessment of epidemiology signatures in overlapping and undefined phenotypes
Measured: At 25 years
Assessment of epidemiology signatures in overlapping and undefined phenotypes
Measured: At 30 years
Assessment of etiology signatures in DCM
Measured: At baseline
Assessment of etiology signatures in DCM
Measured: At 5 years
Assessment of etiology signatures in DCM
Measured: At 10 years
Assessment of etiology signatures in DCM
Measured: At 15 years
Assessment of etiology signatures in DCM
Measured: At 20 years
Assessment of etiology signatures in DCM
Measured: At 25 years
Assessment of etiology signatures in DCM
Measured: At 30 years
Assessment of etiology signatures in HCM
Measured: At baseline
Assessment of etiology signatures in HCM
Measured: At 5 years
Assessment of etiology signatures in HCM
Measured: At 10 years
Assessment of etiology signatures in HCM
Measured: At 15 years
Assessment of etiology signatures in HCM
Measured: At 20 years
Assessment of etiology signatures in HCM
Measured: At 25 years
Assessment of etiology signatures in HCM
Measured: At 30 years
Assessment of etiology signatures in RCM
Measured: At baseline
Assessment of etiology signatures in RCM
Measured: At 5 years
Assessment of etiology signatures in RCM
Measured: At 10 years
Assessment of etiology signatures in RCM
Measured: At 15 years
Assessment of etiology signatures in RCM
Measured: At 20 years
Assessment of etiology signatures in RCM
Measured: At 25 years
Assessment of etiology signatures in RCM
Measured: At 30 years
Assessment of etiology signatures in ACM
Measured: At baseline
Assessment of etiology signatures in ACM
Measured: At 5 years
Assessment of etiology signatures in ACM
Measured: At 10 years
Assessment of etiology signatures in ACM
Measured: At 15 years
Assessment of etiology signatures in ACM
Measured: At 20 years
Assessment of etiology signatures in ACM
Measured: At 25 years
Assessment of etiology signatures in ACM
Measured: At 30 years
Assessment of etiology signatures in LVNC
Measured: At baseline
Assessment of etiology signatures in LVNC
Measured: At 5 years
Assessment of etiology signatures in LVNC
Measured: At 10 years
Assessment of etiology signatures in LVNC
Measured: At 15 years
Assessment of etiology signatures in LVNC
Measured: At 20 years
Assessment of etiology signatures in LVNC
Measured: At 25 years
Assessment of etiology signatures in LVNC
Measured: At 30 years
Assessment of etiology signatures in AMVP
Measured: At baseline
Assessment of etiology signatures in AMVP
Measured: At 5 years
Assessment of etiology signatures in AMVP
Measured: At 10 years
Assessment of etiology signatures in AMVP
Measured: At 15 years
Assessment of etiology signatures in AMVP
Measured: At 20 years
Assessment of etiology signatures in AMVP
Measured: At 25 years
Assessment of etiology signatures in AMVP
Measured: At 30 years
Assessment of etiology signatures in PPCM
Measured: At baseline
Assessment of etiology signatures in PPCM
Measured: At 5 years
Assessment of etiology signatures in PPCM
Measured: At 10 years
Assessment of etiology signatures in PPCM
Measured: At 15 years
Assessment of etiology signatures in PPCM
Measured: At 20 years
Assessment of etiology signatures in PPCM
Measured: At 25 years
Assessment of etiology signatures in PPCM
Measured: At 30 years
Assessment of etiology signatures in AFD
Measured: At baseline
Assessment of etiology signatures in AFD
Measured: At 5 years
Assessment of etiology signatures in AFD
Measured: At 10 years
Assessment of etiology signatures in AFD
Measured: At 15 years
Assessment of etiology signatures in AFD
Measured: At 20 years
Assessment of etiology signatures in AFD
Measured: At 25 years
Assessment of etiology signatures in AFD
Measured: At 30 years
Assessment of etiology signatures in storage and dysmetabolic diseases
Measured: At baseline
Assessment of etiology signatures in storage and dysmetabolic diseases
Measured: At 5 years
Assessment of etiology signatures in storage and dysmetabolic diseases
Measured: At 10 years
Assessment of etiology signatures in storage and dysmetabolic diseases
Measured: At 15 years
Assessment of etiology signatures in storage and dysmetabolic diseases
Measured: At 20 years
Assessment of etiology signatures in storage and dysmetabolic diseases
Measured: At 25 years
Assessment of etiology signatures in storage and dysmetabolic diseases
Measured: At 30 years
Assessment of etiology signatures in mitochondrial diseases
Measured: At baseline
Assessment of etiology signatures in mitochondrial diseases
Measured: At 5 years
Assessment of etiology signatures in mitochondrial diseases
Measured: At 10 years
Assessment of etiology signatures in mitochondrial diseases
Measured: At 15 years
Assessment of etiology signatures in mitochondrial diseases
Measured: At 20 years
Assessment of etiology signatures in mitochondrial diseases
Measured: At 25 years
Assessment of etiology signatures in mitochondrial diseases
Measured: At 30 years
Assessment of etiology signatures in channelopathies with structural changes
Measured: At baseline
Assessment of etiology signatures in channelopathies with structural changes
Measured: At 5 years
Assessment of etiology signatures in channelopathies with structural changes
Measured: At 10 years
Assessment of etiology signatures in channelopathies with structural changes
Measured: At 15 years
Assessment of etiology signatures in channelopathies with structural changes
Measured: At 20 years
Assessment of etiology signatures in channelopathies with structural changes
Measured: At 25 years
Assessment of etiology signatures in channelopathies with structural changes
Measured: At 30 years
Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At baseline
Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 5 years
Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of etiology signatures in overlapping and undefined phenotypes
Measured: At 5 years
Assessment of etiology signatures in overlapping and undefined phenotypes
Measured: At 10 years
Assessment of etiology signatures in overlapping and undefined phenotypes
Measured: At 15 years
Assessment of etiology signatures in overlapping and undefined phenotypes
Measured: At 20 years
Assessment of etiology signatures in overlapping and undefined phenotypes
Measured: At 25 years
Assessment of etiology signatures in overlapping and undefined phenotypes
Measured: At 30 years
Assessment of pathophysiology signatures in DCM
Measured: At baseline
Assessment of pathophysiology signatures in DCM
Measured: At 5 years
Assessment of pathophysiology signatures in DCM
Measured: At 10 years
Assessment of pathophysiology signatures in DCM
Measured: At 15 years
Assessment of pathophysiology signatures in DCM
Measured: At 20 years
Assessment of pathophysiology signatures in DCM
Measured: At 25 years
Assessment of pathophysiology signatures in DCM
Measured: At 30 years
Assessment of pathophysiology signatures in HCM
Measured: At baseline
Assessment of pathophysiology signatures in HCM
Measured: At 5 years
Assessment of pathophysiology signatures in HCM
Measured: At 10 years
Assessment of pathophysiology signatures in HCM
Measured: At 15 years
Assessment of pathophysiology signatures in HCM
Measured: At 20 years
Assessment of pathophysiology signatures in HCM
Measured: At 25 years
Assessment of pathophysiology signatures in HCM
Measured: At 30 years
Assessment of pathophysiology signatures in RCM
Measured: At baseline
Assessment of pathophysiology signatures in RCM
Measured: At 5 years
Assessment of pathophysiology signatures in RCM
Measured: At 10 years
Assessment of pathophysiology signatures in RCM
Measured: At 15 years
Assessment of pathophysiology signatures in RCM
Measured: At 20 years
Assessment of pathophysiology signatures in RCM
Measured: At 25 years
Assessment of pathophysiology signatures in RCM
Measured: At 30 years
Assessment of pathophysiology signatures in ACM
Measured: At baseline
Assessment of pathophysiology signatures in ACM
Measured: At 5 years
Assessment of pathophysiology signatures in ACM
Measured: At 10 years
Assessment of pathophysiology signatures in ACM
Measured: At 15 years
Assessment of pathophysiology signatures in ACM
Measured: At 20 years
Assessment of pathophysiology signatures in ACM
Measured: At 25 years
Assessment of pathophysiology signatures in ACM
Measured: At 30 years
Assessment of pathophysiology signatures in LVNC
Measured: At baseline
Assessment of pathophysiology signatures in LVNC
Measured: At 5 years
Assessment of pathophysiology signatures in LVNC
Measured: At 10 years
Assessment of pathophysiology signatures in LVNC
Measured: At 15 years
Assessment of pathophysiology signatures in LVNC
Measured: At 20 years
Assessment of pathophysiology signatures in LVNC
Measured: At 25 years
Assessment of pathophysiology signatures in LVNC
Measured: At 30 years
Assessment of pathophysiology signatures in AMVP
Measured: At baseline
Assessment of pathophysiology signatures in AMVP
Measured: At 5 years
Assessment of pathophysiology signatures in AMVP
Measured: At 10 years
Assessment of pathophysiology signatures in AMVP
Measured: At 15 years
Assessment of pathophysiology signatures in AMVP
Measured: At 20 years
Assessment of pathophysiology signatures in AMVP
Measured: At 25 years
Assessment of pathophysiology signatures in AMVP
Measured: At 30 years
Assessment of pathophysiology signatures in PPCM
Measured: At baseline
Assessment of pathophysiology signatures in PPCM
Measured: At 5 years
Assessment of pathophysiology signatures in PPCM
Measured: At 10 years
Assessment of pathophysiology signatures in PPCM
Measured: At 15 years
Assessment of pathophysiology signatures in PPCM
Measured: At 20 years
Assessment of pathophysiology signatures in PPCM
Measured: At 25 years
Assessment of pathophysiology signatures in PPCM
Measured: At 30 years
Assessment of pathophysiology signatures in AFD
Measured: At baseline
Assessment of pathophysiology signatures in AFD
Measured: At 5 years
Assessment of pathophysiology signatures in AFD
Measured: At 10 years
Assessment of pathophysiology signatures in AFD
Measured: At 15 years
Assessment of pathophysiology signatures in AFD
Measured: At 20 years
Assessment of pathophysiology signatures in AFD
Measured: At 25 years
Assessment of pathophysiology signatures in AFD
Measured: At 30 years
Assessment of pathophysiology signatures in storage and dysmetabolic diseases
Measured: At baseline
Assessment of pathophysiology signatures in storage and dysmetabolic diseases
Measured: At 5 years
Assessment of pathophysiology signatures in storage and dysmetabolic diseases
Measured: At 10 years
Assessment of pathophysiology signatures in storage and dysmetabolic diseases
Measured: At 15 years
Assessment of pathophysiology signatures in storage and dysmetabolic diseases
Measured: At 20 years
Assessment of pathophysiology signatures in storage and dysmetabolic diseases
Measured: At 25 years
Assessment of pathophysiology signatures in storage and dysmetabolic diseases
Measured: At 30 years
Assessment of pathophysiology signatures in mitochondrial diseases
Measured: At baseline
Assessment of pathophysiology signatures in mitochondrial diseases
Measured: At 5 years
Assessment of pathophysiology signatures in mitochondrial diseases
Measured: At 10 years
Assessment of pathophysiology signatures in mitochondrial diseases
Measured: At 15 years
Assessment of pathophysiology signatures in mitochondrial diseases
Measured: At 20 years
Assessment of pathophysiology signatures in mitochondrial diseases
Measured: At 25 years
Assessment of pathophysiology signatures in mitochondrial diseases
Measured: At 30 years
Assessment of pathophysiology signatures in channelopathies with structural changes
Measured: At baseline
Assessment of pathophysiology signatures in channelopathies with structural changes
Measured: At 5 years
Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of pathophysiology signatures in overlapping and undefined phenotypes
Measured: At baseline
Assessment of pathophysiology signatures in overlapping and undefined phenotypes
Measured: At 5 years
Assessment of pathophysiology signatures in overlapping and undefined phenotypes
Measured: At 10 years
Assessment of pathophysiology signatures in overlapping and undefined phenotypes
Measured: At 15 years
Assessment of pathophysiology signatures in overlapping and undefined phenotypes
Measured: At 20 years
Assessment of pathophysiology signatures in overlapping and undefined phenotypes
Measured: At 25 years
Assessment of pathophysiology signatures in overlapping and undefined phenotypes
Measured: At 30 years
Assessment of genotype-phenotype signatures in DCM
Measured: At baseline
Assessment of genotype-phenotype signatures in DCM
Measured: At 5 years
Assessment of genotype-phenotype signatures in DCM
Measured: At 10 years
Assessment of genotype-phenotype signatures in DCM
Measured: At 15 years
Assessment of genotype-phenotype signatures in DCM
Measured: At 20 years
Assessment of genotype-phenotype signatures in DCM
Measured: At 25 years
Assessment of genotype-phenotype signatures in DCM
Measured: At 30 years
Assessment of genotype-phenotype signatures in HCM
Measured: At baseline
Assessment of genotype-phenotype signatures in HCM
Measured: At 5 years
Assessment of genotype-phenotype signatures in HCM
Measured: At 10 years
Assessment of genotype-phenotype signatures in HCM
Measured: At 15 years
Assessment of genotype-phenotype signatures in HCM
Measured: At 20 years
Assessment of genotype-phenotype signatures in HCM
Measured: At 25 years
Assessment of genotype-phenotype signatures in HCM
Measured: At 30 years
Assessment of genotype-phenotype signatures in RCM
Measured: At baseline
Assessment of genotype-phenotype signatures in RCM
Measured: At 5 years
Assessment of genotype-phenotype signatures in RCM
Measured: At 10 years
Assessment of genotype-phenotype signatures in RCM
Measured: At 15 years
Assessment of genotype-phenotype signatures in RCM
Measured: At 20 years
Assessment of genotype-phenotype signatures in RCM
Measured: At 25 years
Assessment of genotype-phenotype signatures in RCM
Measured: At 30 years
Assessment of genotype-phenotype signatures in ACM
Measured: At baseline
Assessment of genotype-phenotype signatures in ACM
Measured: At 5 years
Assessment of genotype-phenotype signatures in ACM
Measured: At 10 years
Assessment of genotype-phenotype signatures in ACM
Measured: At 15 years
Assessment of genotype-phenotype signatures in ACM
Measured: At 20 years
Assessment of genotype-phenotype signatures in ACM
Measured: At 25 years
Assessment of genotype-phenotype signatures in ACM
Measured: At 30 years
Assessment of genotype-phenotype signatures in LVNC
Measured: At baseline
Assessment of genotype-phenotype signatures in LVNC
Measured: At 5 years
Assessment of genotype-phenotype signatures in LVNC
Measured: At 10 years
Assessment of genotype-phenotype signatures in LVNC
Measured: At 15 years
Assessment of genotype-phenotype signatures in LVNC
Measured: At 20 years
Assessment of genotype-phenotype signatures in LVNC
Measured: At 25 years
Assessment of genotype-phenotype signatures in LVNC
Measured: At 30 years
Assessment of genotype-phenotype signatures in AMVP
Measured: At baseline
Assessment of genotype-phenotype signatures in AMVP
Measured: At 5 years
Assessment of genotype-phenotype signatures in AMVP
Measured: At 10 years
Assessment of genotype-phenotype signatures in AMVP
Measured: At 15 years
Assessment of genotype-phenotype signatures in AMVP
Measured: At 20 years
Assessment of genotype-phenotype signatures in AMVP
Measured: At 25 years
Assessment of genotype-phenotype signatures in AMVP
Measured: At 30 years
Assessment of genotype-phenotype signatures in PPCM
Measured: At baseline
Assessment of genotype-phenotype signatures in PPCM
Measured: At 5 years
Assessment of genotype-phenotype signatures in PPCM
Measured: At 10 years
Assessment of genotype-phenotype signatures in PPCM
Measured: At 15 years
Assessment of genotype-phenotype signatures in PPCM
Measured: At 20 years
Assessment of genotype-phenotype signatures in PPCM
Measured: At 25 years
Assessment of genotype-phenotype signatures in PPCM
Measured: At 30 years
Assessment of genotype-phenotype signatures in AFD
Measured: At baseline
Assessment of genotype-phenotype signatures in AFD
Measured: At 5 years
Assessment of genotype-phenotype signatures in AFD
Measured: At 10 years
Assessment of genotype-phenotype signatures in AFD
Measured: At 15 years
Assessment of genotype-phenotype signatures in AFD
Measured: At 20 years
Assessment of genotype-phenotype signatures in AFD
Measured: At 25 years
Assessment of genotype-phenotype signatures in AFD
Measured: At 30 years
Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
Measured: At baseline
Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
Measured: At 5 years
Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
Measured: At 10 years
Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
Measured: At 15 years
Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
Measured: At 20 years
Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
Measured: At 25 years
Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
Measured: At 30 years
Assessment of genotype-phenotype signatures in mitochondrial diseases
Measured: At baseline
Assessment of genotype-phenotype signatures in mitochondrial diseases
Measured: At 5 years
Assessment of genotype-phenotype signatures in mitochondrial diseases
Measured: At 10 years
Assessment of genotype-phenotype signatures in mitochondrial diseases
Measured: At 15 years
Assessment of genotype-phenotype signatures in mitochondrial diseases
Measured: At 20 years
Assessment of genotype-phenotype signatures in mitochondrial diseases
Measured: At 25 years
Assessment of genotype-phenotype signatures in mitochondrial diseases
Measured: At 30 years
Assessment of genotype-phenotype signatures in channelopathies with structural changes
Measured: At baseline
Assessment of genotype-phenotype signatures in channelopathies with structural changes
Measured: At 5 years
Assessment of genotype-phenotype signatures in channelopathies with structural changes
Measured: At 10 years
Assessment of genotype-phenotype signatures in channelopathies with structural changes
Measured: At 15 years
Assessment of genotype-phenotype signatures in channelopathies with structural changes
Measured: At 20 years
Assessment of genotype-phenotype signatures in channelopathies with structural changes
Measured: At 25 years
Assessment of genotype-phenotype signatures in channelopathies with structural changes
Measured: At 30 years
Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At baseline
Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 5 years
Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
Measured: At baseline
Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
Measured: At 5 years
Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
Measured: At 10 years
Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
Measured: At 15 years
Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
Measured: At 20 years
Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
Measured: At 25 years
Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
Measured: At 30 years
Assessment of arrhythmia signatures in DCM
Measured: At baseline
Assessment of arrhythmia signatures in DCM
Measured: At 5 years
Assessment of arrhythmia signatures in DCM
Measured: At 10 years
Assessment of arrhythmia signatures in DCM
Measured: At 15 years
Assessment of arrhythmia signatures in DCM
Measured: At 20 years
Assessment of arrhythmia signatures in DCM
Measured: At 25 years
Assessment of arrhythmia signatures in DCM
Measured: At 30 years
Assessment of arrhythmia signatures in HCM
Measured: At baseline
Assessment of arrhythmia signatures in HCM
Measured: At 5 years
Assessment of arrhythmia signatures in RCM
Measured: Every 10 years
Assessment of arrhythmia signatures in ACM
Measured: Every 15 years
Assessment of arrhythmia signatures in ACM
Measured: Every 20 years
Assessment of arrhythmia signatures in ACM
Measured: Every 25 years
Assessment of arrhythmia signatures in ACM
Measured: Every 30 years
Assessment of arrhythmia signatures in LVNC
Measured: At baseline
Assessment of arrhythmia signatures in LVNC
Measured: At 5 years
Assessment of arrhythmia signatures in LVNC
Measured: At 10 years
Assessment of arrhythmia signatures in LVNC
Measured: At 15 years
Assessment of arrhythmia signatures in LVNC
Measured: At 20 years
Assessment of arrhythmia signatures in LVNC
Measured: At 25 years
Assessment of arrhythmia signatures in LVNC
Measured: At 30 years
Assessment of arrhythmia signatures in AMVP
Measured: At baseline
Assessment of arrhythmia signatures in AMVP
Measured: At 5 years
Assessment of arrhythmia signatures in AMVP
Measured: At 10 years
Assessment of arrhythmia signatures in AMVP
Measured: At 15 years
Assessment of arrhythmia signatures in AMVP
Measured: At 20 years
Assessment of arrhythmia signatures in AMVP
Measured: At 25 years
Assessment of arrhythmia signatures in AMVP
Measured: At 30 years
Assessment of arrhythmia signatures in PPCM
Measured: At baseline
Assessment of arrhythmia signatures in PPCM
Measured: At 5 years
Assessment of arrhythmia signatures in PPCM
Measured: At 10 years
Assessment of arrhythmia signatures in PPCM
Measured: At 15 years
Assessment of arrhythmia signatures in PPCM
Measured: At 20 years
Assessment of arrhythmia signatures in PPCM
Measured: At 25 years
Assessment of arrhythmia signatures in PPCM
Measured: At 30 years
Assessment of arrhythmia signatures in AFD
Measured: At baseline
Assessment of arrhythmia signatures in AFD
Measured: At 5 years
Assessment of arrhythmia signatures in AFD
Measured: At 10 years
Assessment of arrhythmia signatures in AFD
Measured: At 15 years
Assessment of arrhythmia signatures in AFD
Measured: At 20 years
Assessment of arrhythmia signatures in AFD
Measured: At 25 years
Assessment of arrhythmia signatures in AFD
Measured: At 30 years
Assessment of arrhythmia signatures in storage and dysmetabolic diseases
Measured: At baseline
Assessment of arrhythmia signatures in storage and dysmetabolic diseases
Measured: At 5 years
Assessment of arrhythmia signatures in storage and dysmetabolic diseases
Measured: At 10 years
Assessment of arrhythmia signatures in storage and dysmetabolic diseases
Measured: At 15 years
Assessment of arrhythmia signatures in storage and dysmetabolic diseases
Measured: At 20 years
Assessment of arrhythmia signatures in storage and dysmetabolic diseases
Measured: At 25 years
Assessment of arrhythmia signatures in storage and dysmetabolic diseases
Measured: At 30 years
Assessment of arrhythmia signatures in mitochondrial diseases
Measured: At baseline
Assessment of arrhythmia signatures in mitochondrial diseases
Measured: At 5 years
Assessment of arrhythmia signatures in mitochondrial diseases
Measured: At 10 years
Assessment of arrhythmia signatures in mitochondrial diseases
Measured: At 15 years
Assessment of arrhythmia signatures in mitochondrial diseases
Measured: At 20 years
Assessment of arrhythmia signatures in mitochondrial diseases
Measured: At 25 years
Assessment of arrhythmia signatures in mitochondrial diseases
Measured: At 30 years
Assessment of arrhythmia signatures in channelopathies with structural changes
Measured: At baseline
Assessment of arrhythmia signatures in channelopathies with structural changes
Measured: At 5 years
Assessment of arrhythmia signatures in channelopathies with structural changes
Measured: At 10 years
Assessment of arrhythmia signatures in channelopathies with structural changes
Measured: At 15 years
Assessment of arrhythmia signatures in channelopathies with structural changes
Measured: At 20 years
Assessment of arrhythmia signatures in channelopathies with structural changes
Measured: At 25 years
Assessment of arrhythmia signatures in channelopathies with structural changes
Measured: At 30 years
Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At baseline
Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 5 years
Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of arrhythmia signatures in overlapping and undefined phenotype
Measured: At baseline
Assessment of arrhythmia signatures in overlapping and undefined phenotype
Measured: At 5 years
Assessment of arrhythmia signatures in overlapping and undefined phenotype
Measured: At 10 years
Assessment of arrhythmia signatures in overlapping and undefined phenotype
Measured: At 15 years
Assessment of arrhythmia signatures in overlapping and undefined phenotype
Measured: At 20 years
Assessment of arrhythmia signatures in overlapping and undefined phenotype
Measured: At 25 years
Assessment of arrhythmia signatures in overlapping and undefined phenotype
Measured: At 30 years
Assessment of M-Infl signatures in DCM
Measured: At baseline
Assessment of M-Infl signatures in DCM
Measured: At 5 years
Assessment of M-Infl signatures in DCM
Measured: At 10 years
Assessment of M-Infl signatures in DCM
Measured: At 15 years
Assessment of M-Infl signatures in DCM
Measured: At 20 years
Assessment of M-Infl signatures in DCM
Measured: At 25 years
Assessment of M-Infl signatures in DCM
Measured: At 30 years
Assessment of M-Infl signatures in HCM
Measured: At baseline
Assessment of M-Infl signatures in HCM
Measured: At 5 years
Assessment of M-Infl signatures in HCM
Measured: At 10 years
Assessment of M-Infl signatures in HCM
Measured: At 15 years
Assessment of M-Infl signatures in HCM
Measured: At 20 years
Assessment of M-Infl signatures in HCM
Measured: At 25 years
Assessment of M-Infl signatures in HCM
Measured: At 30 years
Assessment of M-Infl signatures in RCM
Measured: At baseline
Assessment of M-Infl signatures in RCM
Measured: At 5 years
Assessment of M-Infl signatures in RCM
Measured: At 10 years
Assessment of M-Infl signatures in RCM
Measured: At 15 years
Assessment of M-Infl signatures in RCM
Measured: At 20 years
Assessment of M-Infl signatures in RCM
Measured: At 25 years
Assessment of M-Infl signatures in RCM
Measured: At 30 years
Assessment of M-Infl signatures in ACM
Measured: At baseline
Assessment of M-Infl signatures in ACM
Measured: At 5 years
Assessment of M-Infl signatures in ACM
Measured: At 10 years
Assessment of M-Infl signatures in ACM
Measured: At 15 years
Assessment of M-Infl signatures in ACM
Measured: At 20 years
Assessment of M-Infl signatures in ACM
Measured: At 25 years
Assessment of M-Infl signatures in ACM
Measured: At 30 years
Assessment of M-Infl signatures in LVNC
Measured: At baseline
Assessment of M-Infl signatures in LVNC
Measured: At 5 years
Assessment of M-Infl signatures in LVNC
Measured: At 10 years
Assessment of M-Infl signatures in LVNC
Measured: At 15 years
Assessment of M-Infl signatures in LVNC
Measured: At 20 years
Assessment of M-Infl signatures in LVNC
Measured: At 25 years
Assessment of M-Infl signatures in LVNC
Measured: At 30 years
Assessment of M-Infl signatures in AMVP
Measured: At baseline
Assessment of M-Infl signatures in AMVP
Measured: At 5 years
Assessment of M-Infl signatures in AMVP
Measured: At 10 years
Assessment of M-Infl signatures in AMVP
Measured: At 15 years
Assessment of M-Infl signatures in AMVP
Measured: At 20 years
Assessment of M-Infl signatures in AMVP
Measured: At 25 years
Assessment of M-Infl signatures in AMVP
Measured: At 30 years
Assessment of M-Infl signatures in PPCM
Measured: At baseline
Assessment of M-Infl signatures in PPCM
Measured: At 5 years
Assessment of M-Infl signatures in PPCM
Measured: At 10 years
Assessment of M-Infl signatures in PPCM
Measured: At 15 years
Assessment of M-Infl signatures in PPCM
Measured: At 20 years
Assessment of M-Infl signatures in PPCM
Measured: At 25 years
Assessment of M-Infl signatures in PPCM
Measured: At 30 years
Assessment of M-Infl signatures in AFD
Measured: At baseline
Assessment of M-Infl signatures in AFD
Measured: At 5 years
Assessment of M-Infl signatures in AFD
Measured: At 10 years
Assessment of M-Infl signatures in AFD
Measured: At 15 years
Assessment of M-Infl signatures in AFD
Measured: At 20 years
Assessment of M-Infl signatures in AFD
Measured: At 25 years
Assessment of M-Infl signatures in AFD
Measured: At 30 years
Assessment of M-Infl signatures in storage and dysmetabolic diseases
Measured: At baseline
Assessment of M-Infl signatures in storage and dysmetabolic diseases
Measured: At 5 years
Assessment of M-Infl signatures in storage and dysmetabolic diseases
Measured: At 10 years
Assessment of M-Infl signatures in storage and dysmetabolic diseases
Measured: At 15 years
Assessment of M-Infl signatures in storage and dysmetabolic diseases
Measured: At 20 years
Assessment of M-Infl signatures in storage and dysmetabolic diseases
Measured: At 25 years
Assessment of M-Infl signatures in storage and dysmetabolic diseases
Measured: At 30 years
Assessment of M-Infl signatures in mitochondrial diseases
Measured: At baseline
Assessment of M-Infl signatures in mitochondrial diseases
Measured: At 5 years
Assessment of M-Infl signatures in mitochondrial diseases
Measured: At 10 years
Assessment of M-Infl signatures in mitochondrial diseases
Measured: At 15 years
Assessment of M-Infl signatures in mitochondrial diseases
Measured: At 20 years
Assessment of M-Infl signatures in mitochondrial diseases
Measured: At 25 years
Assessment of M-Infl signatures in mitochondrial diseases
Measured: At 30 years
Assessment of M-Infl signatures in channelopathies with structural changes
Measured: At baseline
Assessment of M-Infl signatures in channelopathies with structural changes
Measured: At 5 years
Assessment of M-Infl signatures in channelopathies with structural changes
Measured: At 10 years
Assessment of M-Infl signatures in channelopathies with structural changes
Measured: At 15 years
Assessment of M-Infl signatures in channelopathies with structural changes
Measured: At 20 years
Assessment of M-Infl signatures in channelopathies with structural changes
Measured: At 25 years
Assessment of M-Infl signatures in channelopathies with structural changes
Measured: At 30 years
Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At baseline
Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 5 years
Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of M-Infl signatures in overlapping and undefined phenotypes
Measured: At baseline
Assessment of M-Infl signatures in overlapping and undefined phenotypes
Measured: At 5 years
Assessment of M-Infl signatures in overlapping and undefined phenotypes
Measured: At 10 years
Assessment of M-Infl signatures in overlapping and undefined phenotypes
Measured: At 15 years
Assessment of M-Infl signatures in overlapping and undefined phenotypes
Measured: At 20 years
Assessment of M-Infl signatures in overlapping and undefined phenotypes
Measured: At 25 years
Assessment of M-Infl signatures in overlapping and undefined phenotypes
Measured: At 30 years
Assessment of extracardiac signatures in DCM
Measured: At baseline
Assessment of extracardiac signatures in DCM
Measured: At 5 years
Assessment of extracardiac signatures in DCM
Measured: At 10 years
Assessment of extracardiac signatures in DCM
Measured: At 15 years
Assessment of extracardiac signatures in DCM
Measured: At 20 years
Assessment of extracardiac signatures in DCM
Measured: At 25 years
Assessment of extracardiac signatures in DCM
Measured: At 30 years
Assessment of extracardiac signatures in HCM
Measured: At baseline
Assessment of extracardiac signatures in HCM
Measured: At 5 years
Assessment of extracardiac signatures in HCM
Measured: At 10 years
Assessment of extracardiac signatures in HCM
Measured: At 15 years
Assessment of extracardiac signatures in HCM
Measured: At 20 years
Assessment of extracardiac signatures in HCM
Measured: At 25 years
Assessment of extracardiac signatures in HCM
Measured: At 30 years
Assessment of extracardiac signatures in RCM
Measured: At baseline
Assessment of extracardiac signatures in RCM
Measured: At 5 years
Assessment of extracardiac signatures in RCM
Measured: At 10 years
Assessment of extracardiac signatures in RCM
Measured: At 15 years
Assessment of extracardiac signatures in RCM
Measured: At 20 years
Assessment of extracardiac signatures in RCM
Measured: At 25 years
Assessment of extracardiac signatures in RCM
Measured: At 30 years
Assessment of extracardiac signatures in ACM
Measured: At baseline
Assessment of extracardiac signatures in ACM
Measured: At 5 years
Assessment of extracardiac signatures in ACM
Measured: At 10 years
Assessment of extracardiac signatures in ACM
Measured: At 15 years
Assessment of extracardiac signatures in ACM
Measured: At 20 years
Assessment of extracardiac signatures in ACM
Measured: At 25 years
Assessment of extracardiac signatures in ACM
Measured: At 30 years
Assessment of extracardiac signatures in LVNC
Measured: At baseline
Assessment of extracardiac signatures in LVNC
Measured: At 5 years
Assessment of extracardiac signatures in LVNC
Measured: At 10 years
Assessment of extracardiac signatures in LVNC
Measured: At 15 years
Assessment of extracardiac signatures in LVNC
Measured: At 20 years
Assessment of extracardiac signatures in LVNC
Measured: At 25 years
Assessment of extracardiac signatures in LVNC
Measured: At 30 years
Assessment of extracardiac signatures in AMVP
Measured: At baseline
Assessment of extracardiac signatures in AMVP
Measured: At 5 years
Assessment of extracardiac signatures in AMVP
Measured: At 10 years
Assessment of extracardiac signatures in AMVP
Measured: At 15 years
Assessment of extracardiac signatures in AMVP
Measured: At 20 years
Assessment of extracardiac signatures in AMVP
Measured: At 25 years
Assessment of extracardiac signatures in AMVP
Measured: At 30 years
Assessment of extracardiac signatures in PPCM
Measured: At baseline
Assessment of extracardiac signatures in PPCM
Measured: At 5 years
Assessment of extracardiac signatures in PPCM
Measured: At 10 years
Assessment of extracardiac signatures in PPCM
Measured: At 15 years
Assessment of extracardiac signatures in PPCM
Measured: At 20 years
Assessment of extracardiac signatures in PPCM
Measured: At 25 years
Assessment of extracardiac signatures in PPCM
Measured: At 30 years
Assessment of extracardiac signatures in AFD
Measured: At baseline
Assessment of extracardiac signatures in AFD
Measured: At 5 years
Assessment of extracardiac signatures in AFD
Measured: At 10 years
Assessment of extracardiac signatures in AFD
Measured: At 15 years
Assessment of extracardiac signatures in AFD
Measured: At 20 years
Assessment of extracardiac signatures in AFD
Measured: At 25 years
Assessment of extracardiac signatures in AFD
Measured: At 30 years
Assessment of extracardiac signatures in storage and dysmetabolic diseases
Measured: At baseline
Assessment of extracardiac signatures in storage and dysmetabolic diseases
Measured: At 5 years
Assessment of extracardiac signatures in storage and dysmetabolic diseases
Measured: At 10 years
Assessment of extracardiac signatures in storage and dysmetabolic diseases
Measured: At 15 years
Assessment of extracardiac signatures in storage and dysmetabolic diseases
Measured: At 20 years
Assessment of extracardiac signatures in storage and dysmetabolic diseases
Measured: At 25 years
Assessment of extracardiac signatures in storage and dysmetabolic diseases
Measured: At 30 years
Assessment of extracardiac signatures in mitochondrial diseases
Measured: At baseline
Assessment of extracardiac signatures in mitochondrial diseases
Measured: At 5 years
Assessment of extracardiac signatures in mitochondrial diseases
Measured: At 10 years
Assessment of extracardiac signatures in mitochondrial diseases
Measured: At 15 years
Assessment of extracardiac signatures in mitochondrial diseases
Measured: At 20 years
Assessment of extracardiac signatures in mitochondrial diseases
Measured: At 25 years
Assessment of extracardiac signatures in mitochondrial diseases
Measured: At 30 years
Assessment of extracardiac signatures in channelopathies with structural changes
Measured: At baseline
Assessment of extracardiac signatures in channelopathies with structural changes
Measured: At 5 years
Assessment of extracardiac signatures in channelopathies with structural changes
Measured: At 10 years
Assessment of extracardiac signatures in channelopathies with structural changes
Measured: At 15 years
Assessment of extracardiac signatures in channelopathies with structural changes
Measured: At 20 years
Assessment of extracardiac signatures in channelopathies with structural changes
Measured: At 25 years
Assessment of extracardiac signatures in channelopathies with structural changes
Measured: At 30 years
Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At baseline
Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 5 years
Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of extracardiac signatures in overlapping and undefined phenotypes
Measured: At baseline
Assessment of extracardiac signatures in overlapping and undefined phenotypes
Measured: At 5 years
Assessment of extracardiac signatures in overlapping and undefined phenotypes
Measured: At 10 years
Assessment of extracardiac signatures in overlapping and undefined phenotypes
Measured: At 15 years
Assessment of extracardiac signatures in overlapping and undefined phenotypes
Measured: At 20 years
Assessment of extracardiac signatures in overlapping and undefined phenotypes
Measured: At 25 years
Assessment of extracardiac signatures in overlapping and undefined phenotypes
Measured: At 30 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
Measured: At baseline
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
Measured: At 5 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
Measured: At 10 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
Measured: At 15 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
Measured: At 20 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
Measured: At 25 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
Measured: At 30 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
Measured: At baseline
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
Measured: At 5 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
Measured: At 10 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
Measured: At 15 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
Measured: At 20 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
Measured: At 25 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
Measured: At 30 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
Measured: At baseline
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
Measured: At 5 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
Measured: At 10 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
Measured: At 15 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
Measured: At 20 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
Measured: At 25 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
Measured: At 30 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
Measured: At baseline
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
Measured: At 5 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
Measured: At 10 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
Measured: At 15 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
Measured: At 20 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
Measured: At 25 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
Measured: At 30 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At baseline
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 5 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 10 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 15 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 20 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 25 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 30 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At baseline
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 5 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
Measured: At baseline
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
Measured: At 5 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
Measured: At 10 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
Measured: At 15 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
Measured: At 20 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
Measured: At 25 years
Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
Measured: At baseline
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
Measured: At 5 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
Measured: At 10 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
Measured: At 15 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
Measured: At 20 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
Measured: At 25 years
Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
Measured: At 30 years
Assessment of prognostic signatures in DCM
Measured: At baseline
Assessment of prognostic signatures in DCM
Measured: At 5 years
Assessment of prognostic signatures in DCM
Measured: At 10 years
Assessment of prognostic signatures in DCM
Measured: At 15 years
Assessment of prognostic signatures in DCM
Measured: At 20 years
Assessment of prognostic signatures in DCM
Measured: At 25 years
Assessment of prognostic signatures in DCM
Measured: At 30 years
Assessment of prognostic signatures in HCM
Measured: At baseline
Assessment of prognostic signatures in HCM
Measured: At 5 years
Assessment of prognostic signatures in HCM
Measured: At 10 years
Assessment of prognostic signatures in HCM
Measured: At 15 years
Assessment of prognostic signatures in HCM
Measured: At 20 years
Assessment of prognostic signatures in HCM
Measured: At 25 years
Assessment of prognostic signatures in HCM
Measured: At 30 years
Assessment of prognostic signatures in RCM
Measured: At baseline
Assessment of prognostic signatures in RCM
Measured: At 5 years
Assessment of prognostic signatures in RCM
Measured: At 10 years
Assessment of prognostic signatures in RCM
Measured: At 15 years
Assessment of prognostic signatures in RCM
Measured: At 20 years
Assessment of prognostic signatures in RCM
Measured: At 25 years
Assessment of prognostic signatures in RCM
Measured: At 30 years
Assessment of prognostic signatures in ACM
Measured: At baseline
Assessment of prognostic signatures in ACM
Measured: At 5 years
Assessment of prognostic signatures in ACM
Measured: At 10 years
Assessment of prognostic signatures in ACM
Measured: At 15 years
Assessment of prognostic signatures in ACM
Measured: At 20 years
Assessment of prognostic signatures in ACM
Measured: At 25 years
Assessment of prognostic signatures in ACM
Measured: At 30 years
Assessment of prognostic signatures in LVNC
Measured: At baseline
Assessment of prognostic signatures in LVNC
Measured: At 5 years
Assessment of prognostic signatures in LVNC
Measured: At 10 years
Assessment of prognostic signatures in LVNC
Measured: At 15 years
Assessment of prognostic signatures in LVNC
Measured: At 20 years
Assessment of prognostic signatures in LVNC
Measured: At 25 years
Assessment of prognostic signatures in LVNC
Measured: At 30 years
Assessment of prognostic signatures in AMVP
Measured: At baseline
Assessment of prognostic signatures in AMVP
Measured: At 5 years
Assessment of prognostic signatures in AMVP
Measured: At 10 years
Assessment of prognostic signatures in AMVP
Measured: At 15 years
Assessment of prognostic signatures in AMVP
Measured: At 20 years
Assessment of prognostic signatures in AMVP
Measured: At 25 years
Assessment of prognostic signatures in AMVP
Measured: At 30 years
Assessment of prognostic signatures in PPCM
Measured: At baseline
Assessment of prognostic signatures in PPCM
Measured: At 5 years
Assessment of prognostic signatures in PPCM
Measured: At 10 years
Assessment of prognostic signatures in PPCM
Measured: At 15 years
Assessment of prognostic signatures in PPCM
Measured: At 20 years
Assessment of prognostic signatures in PPCM
Measured: At 25 years
Assessment of prognostic signatures in PPCM
Measured: At 30 years
Assessment of prognostic signatures in AFD
Measured: At baseline
Assessment of prognostic signatures in AFD
Measured: At 5 years
Assessment of prognostic signatures in AFD
Measured: At 10 years
Assessment of prognostic signatures in AFD
Measured: At 15 years
Assessment of prognostic signatures in AFD
Measured: At 20 years
Assessment of prognostic signatures in AFD
Measured: At 25 years
Assessment of prognostic signatures in AFD
Measured: At 30 years
Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At baseline
Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 5 years
Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of prognostic signatures in overlapping and undefined phenotypes
Measured: At baseline
Assessment of prognostic signatures in overlapping and undefined phenotypes
Measured: At 5 years
Assessment of prognostic signatures in overlapping and undefined phenotypes
Measured: At 10 years
Assessment of prognostic signatures in overlapping and undefined phenotypes
Measured: At 15 years
Assessment of prognostic signatures in overlapping and undefined phenotypes
Measured: At 20 years
Assessment of prognostic signatures in overlapping and undefined phenotypes
Measured: At 25 years
Assessment of prognostic signatures in overlapping and undefined phenotypes
Measured: At 30 years
Assessment of response to treatment signatures in DCM
Measured: At baseline
Assessment of response to treatment signatures in DCM
Measured: At 5 years
Assessment of response to treatment signatures in DCM
Measured: At 10 years
Assessment of response to treatment signatures in DCM
Measured: At 15 years
Assessment of response to treatment signatures in DCM
Measured: At 20 years
Assessment of response to treatment signatures in DCM
Measured: At 25 years
Assessment of response to treatment signatures in DCM
Measured: At 30 years
Assessment of response to treatment signatures in HCM
Measured: At baseline
Assessment of response to treatment signatures in HCM
Measured: At 5 years
Assessment of response to treatment signatures in HCM
Measured: At 10 years
Assessment of response to treatment signatures in HCM
Measured: At 15 years
Assessment of response to treatment signatures in HCM
Measured: At 20 years
Assessment of response to treatment signatures in HCM
Measured: At 25 years
Assessment of response to treatment signatures in HCM
Measured: At 30 years
Assessment of response to treatment signatures in RCM
Measured: At baseline
Assessment of response to treatment signatures in RCM
Measured: At 5 years
Assessment of response to treatment signatures in RCM
Measured: At 10 years
Assessment of response to treatment signatures in RCM
Measured: At 15 years
Assessment of response to treatment signatures in RCM
Measured: At 20 years
Assessment of response to treatment signatures in RCM
Measured: At 25 years
Assessment of response to treatment signatures in RCM
Measured: At 30 years
Assessment of response to treatment signatures in ACM
Measured: At baseline
Assessment of response to treatment signatures in ACM
Measured: At 5 years
Assessment of response to treatment signatures in ACM
Measured: At 10 years
Assessment of response to treatment signatures in ACM
Measured: At 15 years
Assessment of response to treatment signatures in ACM
Measured: At 20 years
Assessment of response to treatment signatures in ACM
Measured: At 25 years
Assessment of response to treatment signatures in ACM
Measured: At 30 years
Assessment of response to treatment signatures in LVNC
Measured: At baseline
Assessment of response to treatment signatures in LVNC
Measured: At 5 years
Assessment of response to treatment signatures in LVNC
Measured: At 10 years
Assessment of response to treatment signatures in LVNC
Measured: At 15 years
Assessment of response to treatment signatures in LVNC
Measured: At 20 years
Assessment of response to treatment signatures in LVNC
Measured: At 25 years
Assessment of response to treatment signatures in LVNC
Measured: At 30 years
Assessment of response to treatment signatures in AMVP
Measured: At baseline
Assessment of response to treatment signatures in AMVP
Measured: At 5 years
Assessment of response to treatment signatures in AMVP
Measured: At 10 years
Assessment of response to treatment signatures in AMVP
Measured: At 15 years
Assessment of response to treatment signatures in AMVP
Measured: At 20 years
Assessment of response to treatment signatures in AMVP
Measured: At 25 years
Assessment of response to treatment signatures in AMVP
Measured: At 30 years
Assessment of response to treatment signatures in PPCM
Measured: At baseline
Assessment of response to treatment signatures in PPCM
Measured: At 5 years
Assessment of response to treatment signatures in PPCM
Measured: At 10 years
Assessment of response to treatment signatures in PPCM
Measured: At 15 years
Assessment of response to treatment signatures in PPCM
Measured: At 20 years
Assessment of response to treatment signatures in PPCM
Measured: At 25 years
Assessment of response to treatment signatures in PPCM
Measured: At 30 years
Assessment of response to treatment signatures in AFD
Measured: At baseline
Assessment of response to treatment signatures in AFD
Measured: At 5 years
Assessment of response to treatment signatures in AFD
Measured: At 10 years
Assessment of response to treatment signatures in AFD
Measured: At 15 years
Assessment of response to treatment signatures in AFD
Measured: At 20 years
Assessment of response to treatment signatures in AFD
Measured: At 25 years
Assessment of response to treatment signatures in AFD
Measured: At 30 years
Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At baseline
Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 5 years
Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 10 years
Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 15 years
Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 20 years
Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 25 years
Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Measured: At 30 years
Assessment of response to treatment signatures in overlapping and undefined phenotypes
Measured: At baseline
Assessment of response to treatment signatures in overlapping and undefined phenotypes
Measured: At 5 years
Assessment of response to treatment signatures in overlapping and undefined phenotypes
Measured: At 10 years
Assessment of response to treatment signatures in overlapping and undefined phenotypes
Measured: At 15 years
Assessment of response to treatment signatures in overlapping and undefined phenotypes
Measured: At 20 years
Assessment of response to treatment signatures in overlapping and undefined phenotypes
Measured: At 25 years
Assessment of response to treatment signatures in overlapping and undefined phenotypes
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: At 30 years
Evaluation of efficacy of pharmacological antiarrhythmic treatment on major and minor events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in overlapping and undefined phenotypes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in DCM
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in HCM
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in RCM
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in ACM
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in LVNC
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in AMVP
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in PPCM
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in AFD
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in overlapping and undefined phenotypes
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Identification of criteria for device implants (PM, ICD, S-ICD, CRT-D...) in NICMs patients
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: By 30 years
Identification of the most suitable therapeutic strategies based on indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes
This applies to NICM patients with supraventricular arrhythmias, bradyarrhythmias, or ventricular arrhythmias, with or without M-Inf.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: By 30 years
Identification of the best candidates to multidisciplinary management of NICMs
by identification of the subgroups of patients showing the maximal effects (i.e. lowest incidence of major and minor adverse events) and the minimal risks (i.e. lowest incidence of side effects) following application of multidisciplinary care.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: By 30 years
Indication and timing for device (ICD, CRT-D) implant in primary prevention, based on multidisciplinary, multimodal, multiparametric risk assessment in NICMs, and in relation to different general and etiology-dependent treatments
by identification of the subgroups of patients showing the maximal effects (i.e. lowest incidence of major and minor adverse events) and the minimal risks (i.e. lowest incidence of side effects) following application of multidisciplinary care.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in DCM patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in HCM patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in RCM patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in ACM patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in LVNC patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in PPCM patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in AMVP patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in AFD patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in storage and dysmetabolic diseases patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in mitochondrial diseases patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in channelopathies with structural changes patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in cardiomyopathies associated with overlapping and undefined phenotypes patients, i.e. effects on major and minor events
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in DCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in HCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in RCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in ACM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in LVNC patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in AMVP patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in PPCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in AFD patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in storage and dysmetabolic diseases patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in mitochondrial diseases patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in channelopathies with structural change patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases patients, , i.e. effects on major and minor events
Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in overlapping and undefined phenotypes patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in storage and dysmetabolic diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in channelopathies with structural changes i.e. effects on major and minor events.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes).
Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes).
Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in overlapping and undefined phenotypes i.e. effects on major and minor events.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes).
Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology -specific treatments, including those aimed to target extra - cardiac disease manifestations in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in storage and dysmetabolic diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes) Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in storage and dysmetabolic diseases, mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of replacement therapy, molecular therapy, gene therapy in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in storage and dysmetabolic diseases, mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.
Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of heart transplantation and other treatment for end-stage heart failure in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in DCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in HCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in RCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in ACM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in LVNC, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in AMVP, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in PPCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in AFD, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in storage and dysmetabolic diseases, mitochondrial diseases, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in channelopathies with structural changes, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, i.e. effects on major and minor event i.e. effects on major and minor events.
Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Efficacy of surgical or hemodynamic procedures in overlapping and undefined phenotypes, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Investigation of cardiac device implant in primary and secondary prevention, in all patients, as well as in subgroups with and without M-Infl in NICMs
(indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: By 30 years
Investigation of ablation of cardiac arrhythmias (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes) in NICMs
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: By 30 years
Role of ablation (any technique) on arrhythmic outcomes in NICMs, in all patients, as well as in subgroups with and without arrhythmias and MInfl
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures in HCM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures in ACM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures in LVNC, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures in AMVP, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures in PPCM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures in AFD, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures in storage and dysmetabolic diseases, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures in mitochondrial diseases, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures in channelopathies with structural changes, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures rheumatologic or neuromuscular diseases
i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings.
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years
Indications and optimal timing for any electrophysiological or interventional procedures in overlapping and undefined phenotypes, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.
Measured: By 30 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

30 Jan 201831 Dec 2035

First posted23 Sep 2024
Study start30 Jan 2018
Primary completion31 Dec 2035 (estimated)
Study completion31 Dec 2035 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (34)Papers the sponsor has linked to this study.
Other trials for Non-ischemic CardiomyopathyStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Case-control
Time perspective: Other
Enrolment: 15,000 participants (estimated)
Target duration: 30 Years

IDs, dates and publications

ClinicalTrials.gov ID: NCT06607471
Sponsor's protocol ID: AINICM
Acronym: AINICM
Status last verified: Sep 2024
First submitted: 7 Sep 2024
Last updated: 23 Sep 2024
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided: Requests will be evaluated case by case by the PI.

Publications

Bariani R, Cipriani A, Rizzo S, Celeghin R, Bueno Marinas M, Giorgi B, De Gaspari M, Rigato I, Leoni L, Zorzi A, De Lazzari M, Rampazzo A, Iliceto S, Thiene G, Corrado D, Pilichou K, Basso C, Perazzolo Marra M, Bauce B. 'Hot phase' clinical presentation in arrhythmogenic cardiomyopathy. Europace. 2021 Jun 7;23(6):907-917. doi: 10.1093/europace/euaa343.
PubMed 33313835
Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation. 1996 Sep 1;94(5):983-91. doi: 10.1161/01.cir.94.5.983.
PubMed 8790036
Peretto G, De Luca G, Campochiaro C, Palmisano A, Busnardo E, Sartorelli S, Barzaghi F, Cicalese MP, Esposito A, Sala S. Telemedicine in myocarditis: Evolution of a mutidisciplinary "disease unit" at the time of COVID-19 pandemic. Am Heart J. 2020 Nov;229:121-126. doi: 10.1016/j.ahj.2020.07.015. Epub 2020 Aug 12.
PubMed 32957030
Peretto G, Sala S, Della Bella P. [Diagnostic and therapeutic approach to myocarditis patients presenting with arrhythmias]. G Ital Cardiol (Rome). 2020 Mar;21(3):187-194. doi: 10.1714/3306.32767. Italian.
PubMed 32100731
Della Bella P, Baratto F, Vergara P, Bertocchi P, Santamaria M, Notarstefano P, Calo L, Orsida D, Tomasi L, Piacenti M, Sangiorgio S, Pentimalli F, Pruvot E, De Sousa J, Sacher F, Tritto M, Rebellato L, Deneke T, Romano SA, Nesti M, Gargaro A, Giacopelli D, Peretto G, Radinovic A. Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial. Circulation. 2022 Jun 21;145(25):1829-1838. doi: 10.1161/CIRCULATIONAHA.122.059598. Epub 2022 Apr 3.
PubMed 35369700
Della Bella P, Baratto F, Tsiachris D, Trevisi N, Vergara P, Bisceglia C, Petracca F, Carbucicchio C, Benussi S, Maisano F, Alfieri O, Pappalardo F, Zangrillo A, Maccabelli G. Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: long-term outcome after ablation. Circulation. 2013 Apr 2;127(13):1359-68. doi: 10.1161/CIRCULATIONAHA.112.000872. Epub 2013 Feb 25.
PubMed 23439513
De Luca G, Campochiaro C, Sartorelli S, Peretto G, Dagna L. Therapeutic strategies for virus-negative myocarditis: a comprehensive review. Eur J Intern Med. 2020 Jul;77:9-17. doi: 10.1016/j.ejim.2020.04.050. Epub 2020 May 10.
PubMed 32402564
Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, Stalens C, Sacher F, Babuty D, Trochu JN, Moubarak G, Savvatis K, Porcher R, Laforet P, Fayssoil A, Marijon E, Stojkovic T, Behin A, Leonard-Louis S, Sole G, Labombarda F, Richard P, Metay C, Quijano-Roy S, Dabaj I, Klug D, Vantyghem MC, Chevalier P, Ambrosi P, Salort E, Sadoul N, Waintraub X, Chikhaoui K, Mabo P, Combes N, Maury P, Sellal JM, Tedrow UB, Kalman JM, Vohra J, Androulakis AFA, Zeppenfeld K, Thompson T, Barnerias C, Becane HM, Bieth E, Boccara F, Bonnet D, Bouhour F, Boule S, Brehin AC, Chapon F, Cintas P, Cuisset JM, Davy JM, De Sandre-Giovannoli A, Demurger F, Desguerre I, Dieterich K, Durigneux J, Echaniz-Laguna A, Eschalier R, Ferreiro A, Ferrer X, Francannet C, Fradin M, Gaborit B, Gay A, Hagege A, Isapof A, Jeru I, Juntas Morales R, Lagrue E, Lamblin N, Lascols O, Laugel V, Lazarus A, Leturcq F, Levy N, Magot A, Manel V, Martins R, Mayer M, Mercier S, Meune C, Michaud M, Minot-Myhie MC, Muchir A, Nadaj-Pakleza A, Pereon Y, Petiot P, Petit F, Praline J, Rollin A, Sabouraud P, Sarret C, Schaeffer S, Taithe F, Tard C, Tiffreau V, Toutain A, Vatier C, Walther-Louvier U, Eymard B, Charron P, Vigouroux C, Bonne G, Kumar S, Elliott P, Duboc D. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation. 2019 Jul 23;140(4):293-302. doi: 10.1161/CIRCULATIONAHA.118.039410. Epub 2019 Jun 3.
PubMed 31155932
Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, Bourfiss M, Fortier A, Lie OH, Saguner AM, Svensson A, Andorin A, Tichnell C, Murray B, Zeppenfeld K, van den Berg MP, Asselbergs FW, Wilde AAM, Krahn AD, Talajic M, Rivard L, Chelko S, Zimmerman SL, Kamel IR, Crosson JE, Judge DP, Yap SC, van der Heijden JF, Tandri H, Jongbloed JDH, Guertin MC, van Tintelen JP, Platonov PG, Duru F, Haugaa KH, Khairy P, Hauer RNW, Calkins H, Te Riele ASJM, James CA. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2019 Jun 14;40(23):1850-1858. doi: 10.1093/eurheartj/ehz103.
PubMed 30915475
O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14.
PubMed 24126876
Augusto JB, Eiros R, Nakou E, Moura-Ferreira S, Treibel TA, Captur G, Akhtar MM, Protonotarios A, Gossios TD, Savvatis K, Syrris P, Mohiddin S, Moon JC, Elliott PM, Lopes LR. Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. Eur Heart J Cardiovasc Imaging. 2020 Mar 1;21(3):326-336. doi: 10.1093/ehjci/jez188.
PubMed 31317183
Zorzi A, Perazzolo Marra M, Rigato I, De Lazzari M, Susana A, Niero A, Pilichou K, Migliore F, Rizzo S, Giorgi B, De Conti G, Sarto P, Serratosa L, Patrizi G, De Maria E, Pelliccia A, Basso C, Schiavon M, Bauce B, Iliceto S, Thiene G, Corrado D. Nonischemic Left Ventricular Scar as a Substrate of Life-Threatening Ventricular Arrhythmias and Sudden Cardiac Death in Competitive Athletes. Circ Arrhythm Electrophysiol. 2016 Jul;9(7):e004229. doi: 10.1161/CIRCEP.116.004229.
PubMed 27390211
Peretto G, Busnardo E, Ferro P, Palmisano A, Vignale D, Esposito A, De Luca G, Campochiaro C, Sartorelli S, De Gaspari M, Rizzo S, Dagna L, Basso C, Gianolli L, Della Bella P, Sala S. Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis. JACC Cardiovasc Imaging. 2022 Oct;15(10):1771-1780. doi: 10.1016/j.jcmg.2022.02.029. Epub 2022 May 11.
PubMed 36202457
Peretto G, Sala S, Rizzo S, De Luca G, Campochiaro C, Sartorelli S, Benedetti G, Palmisano A, Esposito A, Tresoldi M, Thiene G, Basso C, Della Bella P. Arrhythmias in myocarditis: State of the art. Heart Rhythm. 2019 May;16(5):793-801. doi: 10.1016/j.hrthm.2018.11.024. Epub 2018 Nov 24.
PubMed 30476544
Wilde AAM, Semsarian C, Marquez MF, Sepehri Shamloo A, Ackerman MJ, Ashley EA, Sternick EB, Barajas-Martinez H, Behr ER, Bezzina CR, Breckpot J, Charron P, Chockalingam P, Crotti L, Gollob MH, Lubitz S, Makita N, Ohno S, Ortiz-Genga M, Sacilotto L, Schulze-Bahr E, Shimizu W, Sotoodehnia N, Tadros R, Ware JS, Winlaw DS, Kaufman ES; Document Reviewers; Aiba T, Bollmann A, Choi JI, Dalal A, Darrieux F, Giudicessi J, Guerchicoff M, Hong K, Krahn AD, MacIntyre C, Mackall JA, Mont L, Napolitano C, Ochoa JP, Peichl P, Pereira AC, Schwartz PJ, Skinner J, Stellbrink C, Tfelt-Hansen J, Deneke T. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm. 2022 Jul;19(7):e1-e60. doi: 10.1016/j.hrthm.2022.03.1225. Epub 2022 Apr 4. No abstract available.
PubMed 35390533

Interested in taking part?

Giovanni Peretto, MD

+39 0226437482

peretto.giovanni@hsr.it

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Not yet recruiting
Pivotal Study to Evaluate Catheter Ablation in Patients With Scar-Related Monomorphic Sustained VT in the Ventricular Ectopy and Reduction in Tachycardia Ablation Studies Program VERITAS SCAR VT
Scar-related Monomorphic Sustained VT
RecruitingObservational study
Non-ischemic Cardiomyopathy Registry, Biobank and Imaging Data Repository
Non-ischemic Cardiomyopathy
Not yet recruiting
Coronary Sinus Reducer Objective Impact on SymptoMs, Ischaemia and miCrovascular Resistance in Non-obstructive Hypertrophic CardioMyopathy
Hypertrophic Cardiomyopathy
RecruitingPhase 1
A Phase I Study of Allogeneic Myocardium-Derived Mesenchymal Stem Cells (HB1011) in Patients With Ischemic Cardiomyopathy
Ischemic Cardiomyopathy
RecruitingPhase 4
Withdrawal of Heart Failure Treatment Patients With Non-ischemic Cardiomyopathy Who Have Been Super-responders to Cardiac Resynchronization Therapy.
Non-ischemic Cardiomyopathy, Cardiac Resynchronisation Therapy (CRT)

All Non-ischemic Cardiomyopathy trials

Study at a glance

From the registry record, last updated by the sponsor on 23 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.
ClinicalTrials.gov ID: NCT06607471
Acronym / sponsor ID: AINICM / AINICM
Conditions: Non-ischemic Cardiomyopathy, Dilated Cardiomyopathy (DCM), Hypertrophic Cardiomyopathy (HCM), Restrictive Cardiomyopathy, Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Left Ventricular Noncompaction
Keywords: Arrhythmogenic cardiomyopathy, Adverse event, Anderson-Fabry disease, Arrhythmic and Inflammatory Non-ischemic cardiomyopathy, Arrhythmogenic mitral valve prolapse, Anti tachycardia pacing, Bradiarrhythmias, Cardiac magnetic resonance
Study type: Observational
Recruitment status: Recruiting
Enrolment: 15,000 participants (estimated)
Lead sponsor: Scientific Institute San RaffaeleUniversity, hospital or other
Study start: 30 Jan 2018 (actual)
Primary completion: 31 Dec 2035 (estimated)
Study completion: 31 Dec 2035 (estimated)
First posted: 23 Sep 2024 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Arrhythmic manifestations account for the arrhythmogenic component of AINICM, which is not limited to ACM proper. In fact, most of the above diseases have a non-arrhythmic clinical presentation and a prevailing tendency to evolve towards a picture of cardiovascular decompensation. Although sudden arrhythmic death has been described throughout the spectrum of AINICM, early arrhythmic manifestations of such diseases have an unknown prevalence, an uncertain association with different disease genotypes and phenotypes, and still uncertain predictivity of long-term arrhythmic risk. At the same time, optimal diagnostic and therapeutic pathways in arrhythmias associated with AINICM are still being studied.
Myocardial inflammation (M-Infl) accounts for the inflammatory component of AINICM, and has recently been described in association with many AINICM on a genetic basis, including undefined and arrhythmic forms. The data is of high interest not only in the diagnostic, but also in prognostic and therapeutic field. In fact, on the one hand the presence of M-Infl seems to have a physio- pathological role in AINICM; on the other, as already known in myocarditis, the optimal therapeutic paths of arrhythmias may differ in patients with and without M-Infl; in particular, also in the light of the preliminary data available in adult and paediatric AINICM, the inflammatory forms are expected to respond better to immunosuppressive therapy, the arrhythmogenic ones to an ablative therapy with frequent need of implantation of cardiac devices.

Detailed description

Improving the diagnostic workup. While genetic test and cardiac magnetic resonance (CMR) constitute the gold standard dagnostic techniques for NICM, it is known that; A) the yield of genetic test is low in NICM; B) the diagnostic performance of CMR may be limited in AINICM, because of cardiac device-related artifacts and/or irregular heartbeat. In this setting, alternative diagnostic techniques, namely computed tomography (CT) scan, positron emission tomography (PET), electroanatomical map (EAM) and endomyocardial biopsy (EMB) may be clinically helpful, as recommended for the investigation of many arrhythmogenic substrates.
Identifying disease-specific signatures. Genotype-phenoype associations are expected to benefit from a multimodal and multiparametric approach, in order to allow etiology-specific features in AINICM. Most of the current signatures are limited to combined genotype-CMR studies. Signatures would likely benefit from implementing additional parameters, including arrhythmia features and myocadial inflammatory status.
Working our models for risk prediction. Outcomes and arrhythmic risk stratification remain uncertain for most NICM. Based on an advanced multimodal workup, multiparametric risk scores may be created and subsequenlty validated, in order to predict the arrhythmic risk of specific cardiomyopathies. This would improve and refine the scores currently available for a limited number of NICM, such as HCM, classic right ventricular ACM, or cardiomyopathies secondary to LMNA gene mutation. Parameters from clinical arrhythmology and cardiac electrophysiology, as well as those related to inflammation, may improve the current status of the art about risk prediction.
Tailoring treatment strategies. A multimodal (i.e. by use of multiple diagnostic techniques) and multidisciplinary (i.e. by means of a team of cardiac electrophysiologists, cardiologists, radiologists, geneticists, immunologists, cardiac pathologists, pediatricians) model may help improving therapeutic strategies in AINICM, as already demonstrated in myocarditis. In detail, treatment options will include guideline-directed cardiological treatment, implantable cardiac devices, antiarrhythmic drugs, immunomodulating agents and catheter ablation of arrhythmias. In this setting, the coordinating center is an internationally recognized third-level referral center for the management of ventricular arrhythmias, and already has advanced facilities, including a dedicated multidisciplinary disease unit for myocarditis and inflammatory cardiomyopathies. In this setting, preliminary evidence suggests a potential benefit from targeting M-Infl even in NICM and AINICM.
Allowing direct comparison among specific NICM subgroups. Extensive inclusion criteria, allowing the entry of all NICM in a common registry with homogeneous variables would enable the direct comparison of different AINICM types, by means of multiparametric and multimodal characterization, for the first time including both the electrophysiological and inflammatory viewpoints. This is expected to significantly advance the status of knowledge in the field of NICM.

Study design

Observational model: Case-control
Time perspective: Other
Target follow-up: 30 Years
Number of arms: 4

Arm	Type	Receives
Arrhythmic and Inflammatory (AINICM)	–	Other: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablationThe AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). The arrhythmogenic and the inflammatory non-ischemic cardiomyopathies (AINICM) will be characterized by means of a multimodal diagnostic workup, which is a combination ofgenetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry.
Non-arrhythmic and inflammatory (INICM)	–	Other: Support treatment, cardiac medical treatment, aetiology-specific treatmentThe inflammatory component will be diagnosed by means of a multidisciplinary workup (i.e. EMB, PET).
Arrhythmic and Non-inflammatory (ANICM)	–	Other: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablationThe arrhythmic component will be diagnosed by means of a multidisciplinary work-up (i.e. SAECG, Arrhythmia monitoring, Stress test, CT scan, EAM, Electrophysiological test)
Non-arrhythmic and Non-inflammatory (NICM)	–	Other: Support treatment, cardiac medical treatment, aetiology-specific treatmentNICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult
Study population: This is an international registry. Enrolment of NICM patients will be performed without restrictions concerning age, gender, ethnicity, social, political, or economical status. Both inpatients and outpatients will be suitable for enrollment. Beyond clinically suspected or proven NICMs, genotype-positive familial cases will be enrolled. The expected sample size is 150000, of whom 5000 will be enrolled at San Raffaele Hospital.

Key inclusion criteria (3 listed)

Written informed consent. For pediatric patients, consent will be obtained by parents, according to the laws applicable in each of the participating countries.
Clinical suspicion of NICM, and/or proven diagnosis of any NICM and/or genotype consistent with any NICM.
NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

Key exclusion criteria (4 listed)

Absent informed consent.
Proven diagnosis of cardiac disease alternative to NICM.
Lack of diagnostic workup suitable for diagnosing NICM, detecting arrhythmias, or detecting M-Infl.
For patients retrospectively enrolled: lack of active status of follow-up at the enrolling center.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablationTreatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.	Other	Arrhythmic and Inflammatory (AINICM), Arrhythmic and Non-inflammatory (ANICM)
Support treatment, cardiac medical treatment, aetiology-specific treatmentTreatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.	Other	Non-arrhythmic and Non-inflammatory (NICM), Non-arrhythmic and inflammatory (INICM)

Primary outcome

Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Time frame: At baseline
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Time frame: At year 5
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Time frame: At year 10
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Time frame: At year 15
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Time frame: At year 20
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Time frame: At year 25
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Time frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At baseline
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 5
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 10
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 15
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 20
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 25
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At baseline
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 5
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 10
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 15
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 20
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 25
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Time frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Identification of DCM-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of DCM-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of DCM-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of DCM-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of DCM-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of DCM-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of DCM-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of HCM-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of HCM-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of HCM-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of HCM-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of HCM-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of HCM-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of HCM-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of RCM-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of RCM-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of RCM-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of RCM-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of RCM-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of RCM-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of RCM-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of ACM-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of ACM-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of ACM-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of ACM-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of ACM-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of ACM-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of ACM-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of LVNC-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of LVNC-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of LVNC-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of LVNC-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of LVNC-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of LVNC-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of LVNC-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AMVP-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AMVP-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AMVP-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AMVP-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AMVP-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AMVP-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AMVP-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of PPCM-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of PPCM-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of PPCM-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of PPCM-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of PPCM-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of PPCM-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of PPCM-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AFD-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AFD-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AFD-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AFD-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AFD-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AFD-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AFD-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of storage and dysmetabolic diseases-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of storage and dysmetabolic diseases-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of storage and dysmetabolic diseases-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of storage and dysmetabolic diseases-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of storage and dysmetabolic diseases-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of storage and dysmetabolic diseases-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of storage and dysmetabolic diseases-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of mitochondrial diseases-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of mitochondrial diseases-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of mitochondrial diseases-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of mitochondrial diseases-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of mitochondrial diseases-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of mitochondrial diseases-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of mitochondrial diseases-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of channelopathies with structural changes-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of channelopathies with structural changes-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of channelopathies with structural changes-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of channelopathies with structural changes-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of channelopathies with structural changes-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of channelopathies with structural changes-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of channelopathies with structural changes-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of overlapping phenotypes-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of overlapping phenotypes-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of overlapping phenotypes-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of overlapping phenotypes-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of overlapping phenotypes-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of overlapping phenotypes-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of overlapping phenotypes-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of undefined phenotypes-specific signatures
Time frame: At baseline
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of undefined phenotypes-specific signatures
Time frame: At year 5
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of undefined phenotypes-specific signatures
Time frame: At year 10
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of undefined phenotypes-specific signatures
Time frame: At year 15
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of undefined phenotypes-specific signatures
Time frame: At year 20
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of undefined phenotypes-specific signatures
Time frame: At year 25
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of undefined phenotypes-specific signatures
Time frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Differences in incidence of major events during follow-up in different NICMs
Time frame: At baseline
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Differences in incidence of major events during follow-up in different NICMs
Time frame: At year 5
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Differences in incidence of major events during follow-up in different NICMs
Time frame: At year 10
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Differences in incidence of major events during follow-up in different NICMs
Time frame: At year 15
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Differences in incidence of major events during follow-up in different NICMs
Time frame: At year 20
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Differences in incidence of major events during follow-up in different NICMs
Time frame: At year 25
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Differences in incidence of major events during follow-up in different NICMs
Time frame: At year 30
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Occurrence of major cardiac events in DCM
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.
Occurrence of major cardiac events in DCM
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in DCM
Time frame: At 3 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in DCM
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in DCM
Time frame: At 15 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in DCM
Time frame: At 20 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in DCM
Time frame: At 25 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in DCM
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in HCM
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in HCM
Time frame: At 3 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in HCM
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in HCM
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in HCM
Time frame: At 15 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in HCM
Time frame: At 20 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in HCM
Time frame: At 25 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in HCM
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in RCM
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in RCM
Time frame: At 3 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in RCM
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in RCM
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in RCM
Time frame: At 15 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in RCM
Time frame: At 20 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in RCM
Time frame: At 25 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in RCM
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in ACM
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in ACM
Time frame: At 3 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in ACM
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in ACM
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in ACM
Time frame: At 15 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in ACM
Time frame: At 20 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in ACM
Time frame: At 25 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in ACM
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in LVNC
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in LVNC
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in LVNC
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in LVNC
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in AMVP
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in AMVP
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in AMVP
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in AMVP
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in PPCM
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in PPCM
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in PPCM
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in PPCM
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in AFD
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in AFD
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in AFD
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in AFD
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in storage and dysmetabolic diseases
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in storage and dysmetabolic diseases
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in storage and dysmetabolic diseases
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in storage and dysmetabolic diseases
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in mitochondrial diseases
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in mitochondrial diseases
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in mitochondrial diseases
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in mitochondrial diseases
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in channelopathies with structural changeschannelopathies with structural changes
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in channelopathies with structural changes
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in channelopathies with structural changes
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in channelopathies with structural changes
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in overlapping phenotypes
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in overlapping phenotypes
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in overlapping phenotypes
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in overlapping phenotypes
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in undefined phenotypes
Time frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in undefined phenotypes
Time frame: At 5 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in undefined phenotypes
Time frame: At 10 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in undefined phenotypes
Time frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Time frame: At 30years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Time frame: At baseline
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Time frame: At 5 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Time frame: At 10 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Time frame: At 15 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Time frame: At 20 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Time frame: At 25 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Time frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

1765 secondary outcomes

Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Time frame: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Time frame: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Time frame: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Time frame: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Time frame: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Time frame: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
Time frame: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
Time frame: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
Time frame: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
Time frame: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
Time frame: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
Time frame: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
Time frame: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
Time frame: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
Time frame: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
Time frame: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
Time frame: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
Time frame: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
Time frame: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
Time frame: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
Time frame: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
Time frame: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
Time frame: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
Time frame: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
Time frame: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
Time frame: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
Time frame: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
Time frame: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
Time frame: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
Time frame: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
Time frame: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
Time frame: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
Time frame: At 20 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
Time frame: At 25 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
Time frame: At 30 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
Time frame: At baseline
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
Time frame: At 5 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
Time frame: At 10 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
Time frame: At 15 years
Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
Time frame: At 20 years

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2024.
Background: PubMed 33313835Bariani R, Cipriani A, Rizzo S, Celeghin R, Bueno Marinas M, Giorgi B, De Gaspari M, Rigato I, Leoni L, Zorzi A, De Lazzari M, Rampazzo A, Iliceto S, Thiene G, Corrado D, Pilichou K, Basso C, Perazzolo Marra M, Bauce B. 'Hot phase' clinical presentation in arrhythmogenic cardiomyopathy. Europace. 2021 Jun 7;23(6):907-917. doi: 10.1093/europace/euaa343.
Background: PubMed 8790036Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation. 1996 Sep 1;94(5):983-91. doi: 10.1161/01.cir.94.5.983.
Background: PubMed 32957030Peretto G, De Luca G, Campochiaro C, Palmisano A, Busnardo E, Sartorelli S, Barzaghi F, Cicalese MP, Esposito A, Sala S. Telemedicine in myocarditis: Evolution of a mutidisciplinary "disease unit" at the time of COVID-19 pandemic. Am Heart J. 2020 Nov;229:121-126. doi: 10.1016/j.ahj.2020.07.015. Epub 2020 Aug 12.
Background: PubMed 32100731Peretto G, Sala S, Della Bella P. [Diagnostic and therapeutic approach to myocarditis patients presenting with arrhythmias]. G Ital Cardiol (Rome). 2020 Mar;21(3):187-194. doi: 10.1714/3306.32767. Italian.
Background: PubMed 35369700Della Bella P, Baratto F, Vergara P, Bertocchi P, Santamaria M, Notarstefano P, Calo L, Orsida D, Tomasi L, Piacenti M, Sangiorgio S, Pentimalli F, Pruvot E, De Sousa J, Sacher F, Tritto M, Rebellato L, Deneke T, Romano SA, Nesti M, Gargaro A, Giacopelli D, Peretto G, Radinovic A. Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial. Circulation. 2022 Jun 21;145(25):1829-1838. doi: 10.1161/CIRCULATIONAHA.122.059598. Epub 2022 Apr 3.
Background: PubMed 23439513Della Bella P, Baratto F, Tsiachris D, Trevisi N, Vergara P, Bisceglia C, Petracca F, Carbucicchio C, Benussi S, Maisano F, Alfieri O, Pappalardo F, Zangrillo A, Maccabelli G. Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: long-term outcome after ablation. Circulation. 2013 Apr 2;127(13):1359-68. doi: 10.1161/CIRCULATIONAHA.112.000872. Epub 2013 Feb 25.
Background: PubMed 32402564De Luca G, Campochiaro C, Sartorelli S, Peretto G, Dagna L. Therapeutic strategies for virus-negative myocarditis: a comprehensive review. Eur J Intern Med. 2020 Jul;77:9-17. doi: 10.1016/j.ejim.2020.04.050. Epub 2020 May 10.
Background: PubMed 31155932Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, Stalens C, Sacher F, Babuty D, Trochu JN, Moubarak G, Savvatis K, Porcher R, Laforet P, Fayssoil A, Marijon E, Stojkovic T, Behin A, Leonard-Louis S, Sole G, Labombarda F, Richard P, Metay C, Quijano-Roy S, Dabaj I, Klug D, Vantyghem MC, Chevalier P, Ambrosi P, Salort E, Sadoul N, Waintraub X, Chikhaoui K, Mabo P, Combes N, Maury P, Sellal JM, Tedrow UB, Kalman JM, Vohra J, Androulakis AFA, Zeppenfeld K, Thompson T, Barnerias C, Becane HM, Bieth E, Boccara F, Bonnet D, Bouhour F, Boule S, Brehin AC, Chapon F, Cintas P, Cuisset JM, Davy JM, De Sandre-Giovannoli A, Demurger F, Desguerre I, Dieterich K, Durigneux J, Echaniz-Laguna A, Eschalier R, Ferreiro A, Ferrer X, Francannet C, Fradin M, Gaborit B, Gay A, Hagege A, Isapof A, Jeru I, Juntas Morales R, Lagrue E, Lamblin N, Lascols O, Laugel V, Lazarus A, Leturcq F, Levy N, Magot A, Manel V, Martins R, Mayer M, Mercier S, Meune C, Michaud M, Minot-Myhie MC, Muchir A, Nadaj-Pakleza A, Pereon Y, Petiot P, Petit F, Praline J, Rollin A, Sabouraud P, Sarret C, Schaeffer S, Taithe F, Tard C, Tiffreau V, Toutain A, Vatier C, Walther-Louvier U, Eymard B, Charron P, Vigouroux C, Bonne G, Kumar S, Elliott P, Duboc D. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation. 2019 Jul 23;140(4):293-302. doi: 10.1161/CIRCULATIONAHA.118.039410. Epub 2019 Jun 3.
Background: PubMed 30915475Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, Bourfiss M, Fortier A, Lie OH, Saguner AM, Svensson A, Andorin A, Tichnell C, Murray B, Zeppenfeld K, van den Berg MP, Asselbergs FW, Wilde AAM, Krahn AD, Talajic M, Rivard L, Chelko S, Zimmerman SL, Kamel IR, Crosson JE, Judge DP, Yap SC, van der Heijden JF, Tandri H, Jongbloed JDH, Guertin MC, van Tintelen JP, Platonov PG, Duru F, Haugaa KH, Khairy P, Hauer RNW, Calkins H, Te Riele ASJM, James CA. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2019 Jun 14;40(23):1850-1858. doi: 10.1093/eurheartj/ehz103.
Background: PubMed 24126876O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14.
Background: PubMed 31317183Augusto JB, Eiros R, Nakou E, Moura-Ferreira S, Treibel TA, Captur G, Akhtar MM, Protonotarios A, Gossios TD, Savvatis K, Syrris P, Mohiddin S, Moon JC, Elliott PM, Lopes LR. Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. Eur Heart J Cardiovasc Imaging. 2020 Mar 1;21(3):326-336. doi: 10.1093/ehjci/jez188.
Background: PubMed 27390211Zorzi A, Perazzolo Marra M, Rigato I, De Lazzari M, Susana A, Niero A, Pilichou K, Migliore F, Rizzo S, Giorgi B, De Conti G, Sarto P, Serratosa L, Patrizi G, De Maria E, Pelliccia A, Basso C, Schiavon M, Bauce B, Iliceto S, Thiene G, Corrado D. Nonischemic Left Ventricular Scar as a Substrate of Life-Threatening Ventricular Arrhythmias and Sudden Cardiac Death in Competitive Athletes. Circ Arrhythm Electrophysiol. 2016 Jul;9(7):e004229. doi: 10.1161/CIRCEP.116.004229.
Individual participant dataSharing planned: Undecided. Requests will be evaluated case by case by the PI.

Related trials for Non-ischemic Cardiomyopathy

Not yet recruiting
Pivotal Study to Evaluate Catheter Ablation in Patients With Scar-Related Monomorphic Sustained VT in the Ventricular Ectopy and Reduction in Tachycardia Ablation Studies Program VERITAS SCAR VT
Scar-related Monomorphic Sustained VT
RecruitingObservational study
Non-ischemic Cardiomyopathy Registry, Biobank and Imaging Data Repository
Non-ischemic Cardiomyopathy
Not yet recruiting
Coronary Sinus Reducer Objective Impact on SymptoMs, Ischaemia and miCrovascular Resistance in Non-obstructive Hypertrophic CardioMyopathy
Hypertrophic Cardiomyopathy
RecruitingPhase 1
A Phase I Study of Allogeneic Myocardium-Derived Mesenchymal Stem Cells (HB1011) in Patients With Ischemic Cardiomyopathy
Ischemic Cardiomyopathy
RecruitingPhase 4
Withdrawal of Heart Failure Treatment Patients With Non-ischemic Cardiomyopathy Who Have Been Super-responders to Cardiac Resynchronization Therapy.
Non-ischemic Cardiomyopathy, Cardiac Resynchronisation Therapy (CRT)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Giovanni Peretto, MD contact

+39 0226437482

peretto.giovanni@hsr.it

Simone Sala, MD contact

+39 0226437483

sala.simone@hsr.it

Paolo Della Bella, MD study chair

San Raffaele Scientific Institute, Milan, Italy

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Non-ischemic Cardiomyopathy and Dilated Cardiomyopathy (DCM), run by Scientific Institute San Raffaele at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 23 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Giovanni Peretto, MD (+39 0226437482, peretto.giovanni@hsr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM (time frame: At baseline). The study lists 569 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06607471, which also lists 34 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2024.